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Uncoupling proteins (UCPs) are highly conserved inner mitochondrial membrane 
proteins that have been found in plants, nematodes, flies, and vertebrates.  UCPs dissipate 
the proton gradient formed by the electron transport chain in an energy-expending 
process that generates heat.  In mammals, the brown fat-specific UCP1 is thought to be 
the dominant, if not the only significant mediator of thermogenic responses.  However, 
adult humans express only negligible amounts of brown fat and UCP1, yet still show 
significant non-shivering thermogenic responses (e.g. amphetamine-induced 
hyperthermia, diet induced thermogenesis, fever).  Thus, the fact that human thermogenic 
mechanisms haven‟t been identified is a huge gap in our understanding of human 
thermoregulation. 
UCP3 is primarily expressed in skeletal muscle, an established thermogenic organ 
which is a major target of amphetamine-induced pathology.  UCP3 knockout mice have a 
near complete loss (~80%) of amphetamine-induced thermogenesis and are completely 
protected from amphetamine-induced death over a range of lethal doses.  With regard to 
mechanisms of UCP3 activation, we observed that norepinephrine and free fatty acids are 
elevated in the bloodstream prior to peak amphetamine-induced hyperthermia.  However, 
viii 
 
little is known about the anatomic location of UCP3-dependent thermogenesis or the 
mechanisms by which fatty acids regulate UCP function.  Thus, we sought to investigate 
the physiology and biochemical activation of UCP3 to establish the thermogenic potential 
of skeletal muscle uncoupling and elucidate the mechanisms of UCP3 function.  The 
overall goal of this research was to identify the tissue target(s) and mechanisms involved 
in amphetamine-induced UCP3-dependent thermogenesis.   
Herein, we show that in addition to a deficit in induced thermogenesis, UCP3-null 
mice also lack responses to other physiologically-relevant stimuli (i.e. catecholamines 
and bacterial pathogens).  Conversely, UCP3 knockout mice, engineered to express 
UCP3 only in skeletal muscle have an augmented thermogenic response to 
amphetamines.  In order to explore UCP3‟s mechanism of activation, we performed a 




dienoyl-CoA isomerase (DCI) 
as a UCP3 binding partner.  DCI, an auxiliary fatty acid oxidation enzyme, protects cells 
from the accumulation of toxic lipid metabolites.  Using immunoprecipitation and fatty 
acid oxidation (FAO) assays, we determined that UCP3 and DCI directly bind in the 
mitochondrial matrix in order to augment lipid metabolism.  These findings support a 
novel model in which skeletal muscle UCP3 is responsible for inducible thermogenesis 
through cooperation with binding partners such as DCI which enhance oxidation of fatty 
acids.  Together, these studies shed light on thermogenic pathways in rodents that are 
likely to be relevant to humans. 
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Chapter 1 – Introduction 
1.1 Bioenergetics 
All living beings must use energy to fuel biologic processes such as movement, 
metabolism, respiration, growth, and reproduction.  The needs of the organism must be 
met through the procurement of energy from external food sources.  It is the study of this 
flow of energy into, through, and subsequently out of an organism that is the field of 
bioenergetics (Campbell 2005).  Animals, in particular, actively harvest their food from 
the environment to obtain chemical energy.  Through digestion and metabolism, chemical 
energy is extracted from food and ultimately results in the production of adenosine 
triphosphate (ATP), a nucleotide that is perhaps the most important form of chemical 
energy currency in animals.  ATP is used to fuel many cellular functions that all 
contribute to the survival of the organism and as such the production of ATP is intimately 
tied to organismal energy demands.  Energy-consuming reactions produce heat as a 
consequence, thus the production of heat correlates to the metabolic rate of the animal.   
The organelle principally responsible for meeting the energy demands of the cell 
is the mitochondrion.  This bi-membranous organelle is the site of cellular respiration, a 
catabolic pathway that consumes oxygen in order to yield high-energy intermediates.  
The process of generating energy in the mitochondria is represented in the simplistic 
pathway in Figure 1.1.  Substrates consumed as food are enzymatically degraded and 
transported into the cell and subsequently into the mitochondria.  These substrates 
undergo metabolism prior to entering the TCA cycle (i.e. tricarboxylic acid cycle, citric 
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acid cycle, or Kreb‟s cycle) then intermediates subsequently contribute electrons to the 
electronc transport chain (ETC).  The ETC is a group of membrane-associated proteins 
that accept and donate electrons in order to actively transport protons (H
+
) from the 
mitochondrial matrix into the intermembrane space.  This enforced concentration of 
protons across the inner mitochondrial membrane creates a membrane potential which is 
then used to fuel the F1/F0 ATP synthase protein that generates ATP from adenosine 
diphosphate (ADP).  Thus, the ingestion and oxidation of substrates is coupled to the 


































Figure 1.1 Mitochondrial Energy Production.  Substrates ingested as food can 
either be stored or used for chemical energy.  The mitochondrion represented in this 
figure is the primary site for energy generation for the cell.   As substrates enter the 
mitochondrion, they undergo metabolism then enter the TCA cycle to produce 
intermediates (malate and succinate) which donate electrons to the ETC.  The ETC 
pumps protons into the inner membrane space in order to create a proton gradient that is 




1.1.1 Metabolic Rate 
In order to determine the energy needs of an organism, it is important to quantify 
the use of energy.  A common principle in bioenergetics is the metabolic rate.  This rate 
is the collective sum of energy required to perform all biologic processes over a unit of 
time.  To some degree, the metabolic rate correlates well with the size of an organism 
with larger organisms having higher metabolic rates.  The metabolic rate is an ever-
fluctuating representation of an animal‟s current energy usage.  In times of high 
metabolism, reproduction, or stress, this rate can increase substantially.  However, the 
rate of energy use needed to power only the most basic life-support functions such as 
breathing and circulation is the basal metabolic rate (BMR).  A living, active organism is 
never operating at its BMR, as any type of activity will consume excess energy.  Thus, 
the metabolic rate is always in flux, increasing with energy demands, and being supplied 
by consumption of energy-producing materials.  The body reacts to changing energy 
requirements through responsive feedback systems whose purpose is to achieve internal 
balance, a principle called „homeostasis‟ (Campbell 2005). 
1.1.2 Homeostasis 
In an effort to achieve balance, homeostatic feedback mechanisms exist to 
respond to and resist changes in the internal environment.  A parameter for the internal 
environment, such as body temperature, will have its own ideal setting or „set point‟.  
However, the constant flux of the internal environment means the set point is never 
achieved for long periods of time.  Rather, there is always slight variation in the set point 
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as the body responds to changes imposed upon it by the activity of the organism, energy 
supply, and the external environment.   Feedback loops exist to respond to changes in set 
points using receptors and effectors.  Receptors serve to detect changes in internal 
environment, and then convey a message through the effectors in order to respond to the 
change.  Positive feedback loops involve a receptor-effector activity that will respond to a 
change by increasing activity in the same direction as the observed change.  Negative 
feedback loops, conversely, will prevent change in the same direction as the initial 
change detected by the receptor.  Body temperature is a parameter of the internal 
environment that is regulated by a set point, receptor-effector relationships, and feedback 
loops.  
Within the hypothalamic brain region there are a collection of nerve cells which 
function as a thermostat for the maintenance of internal body temperature.  These nerve 
cells participate in the positive and negative thermoregulatory feedback loops.  
Temperature-sensing nerve cells are present throughout the body, with high 
concentrations being found in the skin.  In an example of positive feedback, nerve 
receptors in skin may detect increasing body temperature which will cause effectors (e.g. 
sweat glands) to increase their cooling of the body.  In an example of negative feedback, 
the same receptors that sense rising temperatures may trigger other effectors (e.g. 
vascular smooth muscle) to prevent peripheral vessel dilation. 
 Animal species employ different strategies to perform the maintenance of body 
temperature.  Ectotherms, such as fish, reptiles, and amphibians utilize the external 
environment to maintain their internal body temperature.  The metabolic requirements of 
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an ectotherm are relatively low, and as a consequence they have a low metabolic rate.  In 
contrast, the endotherms, which are primarily mammals and birds, rely on internal 
mechanisms.  Endotherms have a high metabolic rate and are able to regulate their 
internal body temperature to a precise degree.  This tight regulation comes at an 
expensive cost energetically, however, and as a substantial benefit endotherms are 
capable of operating in ambient temperatures substantially different from their internal 
set point.  These two metabolic strategies are used to control internal body temperatures 
through behavior, anatomy, and physiologic responses in a process called 
„thermoregulation‟.  While thermoregulation by ectotherms is primarily evidenced 
through changes in their behavior (i.e. locating areas of different ambient temperature, 
feeding), the endothermic strategy is much more complex. 
1.1.3 Thermoregulation 
Thermoregulation is the process by which animals maintain temperature 
homeostasis.  Endotherms perform this function by using anatomical (i.e. insulation, 
circulation) and biochemical (i.e. evaporation, heat production) means to balance heat 
loss versus heat gain (Campbell 2005).  The integument of mammals and birds provides 
insulation from ambient temperatures and is extremely effective at controlling the loss of 
heat through the skin.  In addition, adipose tissue immediately beneath the skin can 
augment this protection.  Some animals also have fur or feathers to provide further 
insulation against the external environment.  The circulatory system carries nutrient-rich 
blood to distant tissues.  This transport function is also utilized in thermoregulation to 
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either cool (i.e. shunting blood away from the core) or heat (i.e. shunting blood to the 
core) the body through the movement of blood.  Biochemical processes are also utilized 
by endotherms to maintain temperature homeostasis.  Because water absorbs heat when it 
evaporates, saliva and the production of sweat are used for evaporative heat loss.  Finally, 
organisms can also employ metabolic heat production, also known as „thermogenesis.‟  
1.2 Thermogenesis 
The regulation of core body temperature is a tightly-controlled process that is 
proposed to be governed by the hypothalamic-pituitary-thyroid (HPT) axis and the 
sympathetic nervous system (SNS) (Sprague, Banks et al. 2003).  Although all of the 
molecular mediators of thermogenesis still remain to be identified, several have been 
proposed including adrenergic receptors and mitochondrial uncoupling proteins (UCPs).  
Traditional thermogenesis, or non-shivering thermogenesis, is a normal physiological 
process.  In rodents, a major contributor to non-shivering thermogenesis is uncoupling 
protein 1 (UCP1) which is present in brown adipose tissue (BAT).  Humans, however, 
have negligible amounts of BAT or UCP1 but still have the capacity for non-shivering 
thermogenesis.  Other uncoupling protein homologs such as UCP3 (found in skeletal and 
heart muscle) may be responsible for this effect, although this is a matter of intense 
scientific debate.  In addition to rapid temperature-adjusting responses such as non-
shivering thermogenesis, the concepts of body temperature regulation and energy 
expenditure are intimately related to homeostasis.   
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 A current focus of intense research in the realm of obesity and weight loss is 
adaptive thermogenesis.  The expenditure of energy as heat (thermogenesis) can be 
studied in carefully controlled trials that examine the subject‟s change in weight versus 
their energy intake. Several researchers have found that dramatic changes in diet often 
do not lead to dramatic changes in fat content or weight, purportedly due to adaptive 
thermogenesis (Major, Doucet et al. 2007).  This adaptation to a dramatic change in 
substrate availability can lead to no effect or a paradoxical effect upon body weight and 
fat composition.  The theory of adaptive thermogenesis is that the body has the capacity 
to regulate energy expenditure under normal physical conditions.  Drastic changes in 
energy intake, such as during dieting or starvation, do not always have the anticipated 
effect (loss of fat reserves) due to the stabilizing effect of adaptive thermogenesis.  This is 
proposed to be a significant obstacle to obesity treatments and weight loss regimens 
(Major, Doucet et al. 2007). 
 Although traditionally thermogenesis is thought of as the ability to produce heat, 
it is perhaps more appropriate to consider it as the ability to regulate the core body 
temperature (Campbell 2005).  In addition to raising body temperature, there are several 
examples of animals that prevent thermogenesis to survive adverse conditions by 
lowering core body temperature.   This phenomenon that occurs in rodents, marsupials, 
and small mammals is known as hibernation.  Hibernation is characterized by a shift in 
substrate utilization from predominantly carbohydrate to entirely lipid (i.e. fat stores) 
(Andrews 2007).  This dramatic shift is thought to be induced at least partly by 
environmental factors such as cold temperatures, scarcity of food, and shortening 
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daylight hours.  Although induction of hibernation may have environmental influence, 
widespread molecular differences have been observed in animals in torpid versus active 
states.    Like other forms of thermoregulation, hibernation is thought to also be 
controlled by the master regulator thyroid hormone (TH).  Circulating thyroid hormone 
levels are thought to drop due to an increase in the serum level of thyroxine binding 
globulin (TBG) (Andrews 2007).  Thyroid hormone has also been proposed to play an 
important role in mediating the hyperthermic responses in various heat illnesses including 
amphetamine-induced pathologic hyperthermia (Sprague, Banks et al. 2003). 
1.2.1 Hyperthermia and Heat Illnesses  
As discussed previously, thermoregulation is a well-controlled process that has 
the capacity to adapt either rapidly (e.g. muscle movement or hormone release) or 
transcriptionally (i.e. gene expression of proteins) to alter the metabolic state and 
maintain homeostasis.  Fever is perhaps the most common heat-related symptom that 
occurs under this tight control.  Fever is a common response to the presence of pathogens 
or to endogenous systemic inflammation.  Fever is defined as an elevated body 
temperature beyond the range considered normal (usually 39.3°C).  In general, fever is 
viewed as a negative clinical finding although it reportedly is beneficial for the host 
immune response (Aiyagari and Diringer 2007).  Aberrations in the regulation of this 
process can lead to core body temperatures in excess of 104°F that can lead to seizures 
and neurological deficits.  
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 Some pathologically altered states can lead to more severe heat-related illnesses 
such as heat stroke and malignant hyperthermia.  Heat stroke is usually caused by an 
inability to dissipate heat that is being produced in the body.  This may occur by physical 
exertion in a warm climate, or even without strenuous exercise (Jardine 2007).  
Malignant hyperthermia, conversely, usually occurs in response to pharmacological 
triggers in a genetically-susceptible individual.  Affected individuals usually have 
mutations of the ryanodine receptor that is present in smooth endoplasmic reticulum 
(Jardine 2007).  In this illness, excessive futile calcium cycling in the sarcoplasm of 
skeletal muscle generates heat, much in the same way “futile” mitochondrial proton flux 
generates heat – energy that is released from ion flux, but not consumed – and is given 
off as heat.  Dantrolene inhibits the ryanodine receptor and is the established treatment 
for malignant hyperthermia (Blank and Boggs 1993).  Both of these conditions are easily 
treated with either removal of the heat stimulus or administration of dantrolene, 
respectively.   A unique and less treatable type of hyperthermia emerges in response to 
toxic doses of amphetamines, such as methamphetamine and MDMA.  
1.2.2 Investigational Models of Thermogenesis 
The study of thermogenic mechanisms in animals demands the need to employ 
models that mimic naturally-occurring, physiologic phenomena.   Currently, the most 
utilized investigational models are diet-induction, cold exposure, and adrenergic 
stimulation.  Although these models represent distinct methods, they all intersect at 
downstream pathways of thermogenesis.  The concept of diet-induced thermogenesis was 
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first realized when rats fed a high-fat, high-sugar diet (i.e. “cafeteria diet”) failed to 
increase their body weight consistent with their caloric intake (Rothwell and Stock 1979).  
This lack of weight gain has been attributed to adaptive thermogenesis by specific tissues.  
The pre-feeding of cafeteria style foods has routinely been employed to study diet-
induced thermogenesis, although this phenomenon has recently been challenged (Kozak 
2010).  The exposure of a laboratory animal to cold environments has been used 
extensively to study adaptive mechanisms (Roberts and Smith 1967).  This method was 
first described during the study of hibernation (Smith and Hock 1963).  Lastly, the 
administration of amphetamines or drugs that cause release of endogenous adrenergics 
(i.e. catecholamines such as norepinephrine, epinephrine, and dopamine) has been used 
for thermogenic studies.  Norepinephrine administration was used in pivotal experiments 
to show that cold-acclimated mice shunt blood to target organs to increase heat (Foster 
and Frydman 1978).  Amphetamines can be viewed as „effectors‟ downstream of both hi-
fat feeding and cold-exposure.   
1.2.3 Brown Adipose Tissue  
Brown adipose tissue (BAT) is a well-circumscribed tissue present in several 
peripherally-distributed depots (e.g. intraspacular, cervical, perirenal, periaortic).  The 
intrascapular depot is the largest single collection, accounting for approximately 25% of 
all BAT (Smith and Horwitz 1969).  In contrast to white adipose tissue (WAT), which is 
primarily a storage reservoir for fatty acids, the BAT tissue morphology suggests a more 
active function.  Using electron microscopy, BAT has been observed to contain many 
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mitochondria, indicating that it is an energetically demanding tissue (Smith and Horwitz 
1969).   
The theory that BAT was thermogenic first began when it was observed to 
undergo changes in morphology (i.e. hypertrophy, hypervascularization, engorgement) 
when exposed to cold temperatures (Smith and Horwitz 1969).  Later it was established 
that blood flow was specifically increased to BAT after cold exposure (Foster and 
Frydman 1978).  Subsequently, it was speculated that the prominence of BAT in newborn 
mammals evolved as a protective measure to counteract low ambient temperatures 
(Casteilla, Champigny et al. 1989).  Thus, its role in the maintenance of body temperature 
was speculated although its utility was thought to be important for very specific 
scenarios; 1) in neonates for nonshivering thermogenesis, 2) after cold exposure to 
stabilize body temperatures, or 3) to facilitate arousal of the hibernating animal (Smith 
and Horwitz 1969).    Recent evidence suggest that BAT exists in humans even 
independently of the scenarios mentioned above (Nedergaard, Bengtsson et al. 2007; 
Zingaretti, Crosta et al. 2009).  However, the prevalence in the general population and the 
significance of its existence still remains to be established. 
1.2.4 Thermogenin, the First UCP 
Although BAT was well-described as a thermogenic tissue which responds to 
cold-acclimation (Foster and Frydman 1978),  the mechanism responsible for this effect 
was initially unknown.  As other groups clearly showed a proliferation of mitochondria in 
BAT (Smith and Horwitz 1969), research into the mechanisms of thermogenesis focused 
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on this organelle.  Isolated mitochondria from BAT exhibited a pattern of uncontrolled 
respiration that appeared to be in excess of that required to meet the energy demands of 
the cell (Hittelman, Lindberg et al. 1969; Rafael, Ludolph et al. 1969).  This research 
showed that the respiration could be inhibited by adding purine nucleotides or fatty acid-
sequestering bovine serum albumin (Rafael, Ludolph et al. 1969).  Later it was 
discovered that radiolabeled nucleotides associated with the outer surface of the inner 
mitochondrial membrane (Nicholls 1976).  Based upon these data, Nicholls and 
colleagues concluded that a protein present on the inner mitochondrial membrane was 
responsible for the high respiratory capacity of BAT mitochondria.  Using a technique 
referred to as photoaffinity labeling, the molecule was identified as a 32 kilodalton 
protein which accounted for approximately 10% of total mitochondrial protein content 
(Nicholls 1976).  This protein was uncoupling protein 1 (UCP1), the archetypical 
uncoupling protein, also called thermogenin. 
UCP1 is by far the most well-studied of the UCP family and the numerous 
investigations performed since its discovery have yielded significant insight into its 
structure, function, and contribution to mammalian physiology.  All uncoupling proteins 
are members of the SLC25 solute carrier family of proteins that share a similar structure 
(Figure 1.2).  These proteins are integrated into the inner mitochondrial membrane that 
separates the mitochondrial matrix from the intermembrane space.  UCP1 has been 
shown to dissipate the proton gradient across the mitochondrial inner membrane.  By 
increasing the proton conductance of the membrane, energy is wasted as heat (Cannon 
and Nedergaard 2004).  The activity of UCP1 is inhibited at physiological levels of 
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purine nucleotides (i.e. adenosine phosphates, guanosine phosphates).  This inhibition is 
quickly released as the protein encounters an increasing concentration of fatty acids in the 
mitochondrial matrix.  Simply stated, the activation of an uncoupling protein consumes 
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Figure 1.2  The SLC25 Solute Carrier Mitochondrial Proteins.  This family of 
inner mitochondrial membrane proteins transport molecules between the mitochondrial 
matrix and the intermembrane space.  Three tandem repeats each have two 
transmembrane domains and both the N and C termini localize to the intermembrane 








Figure 1.3  Uncoupling Protein Function.  As the electron transport chain (ETC) 
generates the proton gradient necessary to power the synthesis of ATP, uncoupling 
proteins can intervene to “uncouple” this system.  Protons used to form the gradient in the 
inner membrane space are transported back into the mitochondrial matrix by UCP in a 
reaction that gives off heat.  The metabolism of substrates increases, as does the 




1.2.5 Uncoupling Protein Homologues 
The uncoupling proteins are a subset of the mitochondrial solute carrier family of 
proteins.  Since the discovery of UCP1 in 1976, other homologues have been identified 
based upon their protein sequences (UCP1-5) (Figure 1.4).  Whereas UCP1 is expressed 
solely in BAT, other UCPs have distinct tissue expression patterns.  UCP2 was originally 
identified in 1997 and is ubiquitously expressed (Fleury, Neverova et al. 1997).  UCP3, 
also identified in 1997, is primarily expressed in skeletal muscle and to a lesser degree in 
heart and BAT (Vidal-Puig, Solanes et al. 1997; Boss, Giacobino et al. 1998).  Initial 
excitement that these proteins would behave in a manner similar to UCP1 arose from the 
analysis of conserved domains purported to be important for proton conductance and 
nucleotide binding.  Relatively little is known about the most recent UCP family 
members, UCP4 and UCP5.  UCP4 is expressed in virtually all areas of the brain and 
spinal cord (Mao, Yu et al. 1999).  UCP5, also known as BMCP1, is expressed in specific 
brain regions such as the cortex, hippocampus, and thalamus (Kim-Han, Reichert et al. 
2001).  Both UCP4 and UCP5 share low sequence homology with UCP1, and more 






         
 
 
Figure 1.4  The Uncoupling Protein Homologs.  The prototypical uncoupling 
protein 1 (UCP1) was the first identified in brown adipose tissue (BAT).  Subsequently 
UCP2 (UBI, ubiquitous expression) and UCP3 were discovered (SKM, skeletal muscle; 
HRT, heart; BAT).  Both UCP4 and UCP5 have only ~30% homology with UCP1 
andtheir expression is limited to the central nervous system.k  
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1.2.6 Uncoupling Protein 3   
As mentioned above, the UCP1 homolog UCP3 was discovered in 1997.  Its 
characterization revealed that it is present in specific tissues, in contrast to the ubiquitous 
expression pattern of UCP2 (Boss, Samec et al. 1997).  This was of particular interest 
because it was found mainly in established thermogenic organs, skeletal muscle, brown 
adipose tissue, and heart (Boss, Samec et al. 1997).  Initial studies supported a role for 
UCP3 in thermogenesis because it was found to be upregulated in response to cold-
exposure in a manner similar to UCP1 (Larkin, Mull et al. 1997).  However, subsequent 
investigations concluded that mice genetically engineered to lack UCP3 had no deficit in 
body temperature regulation, notably in response to cold (Golozoubova, Hohtola et al. 
2001).  Thus, the actual function of UCP3 has been a source of controversy.  No 
definitive physiologic or biochemical function for UCP3 has been established. 
1.3 Physiological Functions of Uncoupling Protein 3 
Previous studies have provided conflicting hypotheses on whether UCP3 is a 
thermogenic protein (Larkin, Mull et al. 1997; Golozoubova, Hohtola et al. 2001).  In 
addition, some groups have reported that the upregulation of UCP3 during fasting 
(Samec, Seydoux et al. 1998; Cadenas, Buckingham et al. 1999; Gong, Monemdjou et al. 
2000) is not congruent with the energy-wasting consequence of UCP3 activation (Azzu, 
Jastroch et al. 2010).  Another piece of evidence to refute a role for UCP3 in adaptive 
thermogenesis is the presence of its homologues in fish (Stuart, Harper et al. 1999) and 
plants (Laloi, Klein et al. 1997).  Both fish and plants are ectotherms which are generally 
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thought to not possess the capacity for adaptive thermogenesis, although recent examples 
of uncoupling protein function in plants refute this (Smith, Ratcliffe et al. 2004; Ito-
Inaba, Hida et al. 2008).  Finally, what is regarded as the most definitive study on the 
lack of UCP3‟s thermogenic potential showed that UCP3 knockout mice retain the 
capacity for nonshivering, adaptive thermogenesis in response to cold (Vidal-Puig, Grujic 
et al. 2000).  However, some evidence does exist to support the integration of UCP3 into 
existing thermoregulatory pathways.   
The Djungarian hamster, which specifically lacks UCP3 in BAT, was found to have 
a defect in cold-tolerance despite the presence of active, functional UCP1 (Nau, Fromme 
et al. 2008).  The interpretation of these results is difficult as this model has not been 
employed for the majority of other studies on the function of UCP1 and UCP3.  Also, the 
UCP3 deletion in the Djungarian hamster is caused by missense mutation, rather than a 
genetically engineered knockout.  Thus, the replication of these studies in traditional 
inbred mouse strains is needed.  Another important and socially-relevant finding of UCP3 
function arose from studies of the amphetamine compound 3,4-
methylenedioxymethamphetamine (Ecstasy, MDMA).  A principal observation in the 
toxicity evoked by MDMA and related amphetamines is an inability to regulate body 
temperature subsequently leading to life-threatening hyperthermia and death.   Mice 
lacking UCP3 had a blunted thermogenic response to MDMA and were completely 
protected from death after MDMA administration (Mills, Banks et al. 2003). 
The studies performed to date to investigate the physiologic function of UCP3 have 
left several unanswered questions.  Previous reports on the thermogenic potential of 
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UCP3 have utilized the cold-exposure model to suggest that UCP3 is not required for 
adaptive thermogenesis (Vidal-Puig, Grujic et al. 2000; Golozoubova, Hohtola et al. 
2001).  In these investigations, mice lacking UCP3 were subjected to cold ambient 
temperatures and they were able to mount a thermogenic response sufficient to maintain 
internal temperatures at a constant level.  These studies provide important evidence that 
UCP3 is not required for cold-induced thermogenesis but do not address the role of UCP3 
in responding to other stimuli.  These studies also ignore the established role of UCP1 in 
thermogenesis and do not test for UCP3 effects.  In modern society, the thermogenic 
response to dangerously cold ambient temperatures is perhaps a scenario that is less 
meaningful to the human population than other more physiologically-relevant triggers 
(i.e. pathogen-induced fever, endogenous catecholamine release). 
The most definitive study showing a positive UCP3-dependent thermogenic effect 
illustrated that amphetamines are perhaps the most potent stimuli (Mills, Banks et al. 
2003).  Although this report provides clear evidence for the involvement of UCP3 in 
amphetamine-induced thermogenesis, the organ responsible has not been identified.  
UCP3 is expressed primarily in skeletal muscle, heart, and to a lesser degree in BAT 
(Boss, Samec et al. 1997).  Because previous reports have shown that BAT function (i.e. 
nonshivering, adaptive thermogenesis) is not negatively affected in a UCP3 knockout 
animal, it is important to differentiate the organ responsible for the strong amphetamine-
induced toxicity phenotype (i.e. rule out or provide evidence for skeletal muscle UCP3 as 
the effector organ). 
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1.4 Biochemical Functions of Uncoupling Protein 3 
The biochemical functions of UCP3 have been explored in numerous previous 
studies.  It has been proposed to function in relieving oxidative stress, protecting against 
insulin resistance, and increasing fatty acid oxidation.  Very few conclusive findings have 
been accepted by the scientific community.  The majority of work on UCP3 function has 
been devoted to the mitigation of reactive oxygen species (ROS).  ROS form when 
availability of substrates exceeds energy demands.  These dangerous by-products can 
attack cellular proteins, DNA, and lipids leading to dysfunction or cell death.  Evidence 
for the capacity of UCP3 to deal with high ROS levels comes from  studies that show 
UCP3 is activated by endogenous (Talbot, Hanuise et al. 2003; Talbot, Lambert et al. 
2004) as well as exogenous ROS (Echtay, Roussel et al. 2002), and lipid peroxides 
(Murphy, Echtay et al. 2003).  In vivo models have illustrated that UCP3 decreases ROS-
induced protein damage in skeletal muscle (Barreiro, Garcia-Martinez et al. 2009) and 
may act during times of high ROS levels such as exercise (Jiang, Zhang et al. 2009). 
 Another proposed biochemical function of UCP3 is the amelioration of insulin 
resistance.  This theoretical action is of great interest in light of the tremendous societal 
burden currently ongoing as a result of obesity and Type 2 diabetes mellitus (T2DM).  
Insulin resistance in skeletal muscle is the major cause of T2DM (Chan and Harper 
2006).  Evidence for this protection conferred by UCP3 comes from studies which show 
that mice overexpressing UCP3 (specifically in skeletal muscle) are protected from 
obesity and insulin resistance (Son, Hosoda et al. 2004).  Current standard of care 
treatment for T2DM involves the use of PPAR agonists to treat insulin resistance.  Insulin 
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resistance is a physiologic phenomenon during which the natural protein insulin becomes 
less effective at eliciting the import and metabolism of glucose and fatty acids.  The 
efficacy of this treatment may be explained by the upregulation of UCP3 by PPAR 
treatment in diabetic patients (Schrauwen, Mensink et al. 2006). 
Lastly, a role for UCP3 in fatty acid metabolism has been investigated.  Some 
groups have argued that UCP3 may act as a fatty acid transporter (Himms-Hagen and 
Harper 1999; Himms-Hagen and Harper 2001; Schrauwen, Hoeks et al. 2006) while 
others have contested this notion (Seifert, Bezaire et al. 2008).  Work performed in mice 
with UCP3 overexpressed specifically in skeletal muscle have shown an increase in fatty 
acid transport and oxidation (Bezaire, Spriet et al. 2005).  Likewise others have shown 
increased fatty acid oxidation during fasting was UCP3-dependent (Seifert, Bezaire et al. 
2008).  The capacity for UCP3 to increase oxidation/metabolism of fatty acids is of 
particular importance given the global epidemic of obesity.  This potential function 
should be further explored to determine the therapeutic possibilities for targeting relevant 
human diseases. 
1.5 Concluding Remarks  
The energy demands of an organism are determined by its size, activity, 
environment, and physiology.  The maintenance of body heat, as in endotherms, is an 
energetically costly process.  In order to maintain vital functions such as cell 
maintenance, breathing, and circulation, an organism must achieve its BMR.  The BMR 
is the sum of all energy required to perform necessary cellular processes while the 
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organism is at rest.  The ability of an organism to exceed this basal metabolic rate in 
times of greater energetic needs varies substantially, but ultimately depends on the 
availability of substrates.  The mitochondria are the organelles which are principally 
responsible for the generation of ATP, the high-energy intermediates used to fuel the 
majority of cellular operations.  ATP is generated via the mitochondrial membrane 
electron transport chain and oxidative phosphorylation (Figure 1.1).  The generation of 
ATP relies on the consumption of substrates (i.e. food), however this process is not 100% 
efficient.  The mitochondrial uncoupling proteins (UCPs) are inner membrane proteins 
that can interfere with or uncouple the generation of ATP by dissipating the proton 
gradient that fuels ATP synthesis (Figure 1.3).  This process promotes a rapid increase in 
oxygen consumption and wastes substrate oxidation as heat.  Thus, the activation of 
uncoupling proteins results in heat production, energy-wasting, and increased metabolism 
of substrates. 
The generation of heat, or thermogenesis, is a crucial physiologic characteristic of 
endotherms.  The mediation of adaptive thermogenesis in BAT by the archetypal UCP1 is 
well-established.  Other UCP1 homologs, such as UCP3, are still in need of further 
investigation.  Previous studies have shown that UCP3 is primarily expressed in skeletal 
muscle (Larkin, Mull et al. 1997; Vidal-Puig, Solanes et al. 1997) and does not have the 
same function as UCP1 (Vidal-Puig, Grujic et al. 2000).  However, UCP3 may still be 
important for other types of thermogenesis such as under different experimental 
conditions or with different stimuli.  Other possible roles for UCP3 include the mitigation 
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of reactive oxygen species, the protection from insulin resistance, or the augmentation of 
fatty acid transport or oxidation.   
Two main gaps in our understanding of UCP3 function and activity exist.  From an 
anatomical and physiological standpoint, the only clear UCP3-dependent phenotypical 
observation has been observed in response to amphetamines (Mills, Banks et al. 2003).  
UCP3 knockout animals lose the hyperthermic response to amphetamines that is seen in 
wild type animals.  However, UCP3 is expressed in brown fat as well as skeletal muscle, 
both established thermogenic organs.  This investigation will attempt to address the 
contribution of UCP3 in BAT versus skeletal muscle to the amphetamine-induced 
thermogenic phenotype.  Although many studies have been performed exploring UCP3 
function, none have proposed a mechanism that involves intimate cooperation with other 
proteins.  Another goal of this investigation was to study the mechanism of proposed 
UCP3 functions through the interrogation of protein-protein interactions.  Collectively, 
the data shown in this investigation will contribute to the understanding of UCP3 




Chapter 2 – Methods and materials 
2.1 Chemicals and Reagents 
Unless otherwise stated, all reagents and chemicals were obtained from Sigma-
Aldrich (St. Louis, MO).   
2.2 Yeast Two Hybrid 
This screening was performed according to the method of Pierrat et al. (Pierrat, 
Ito et al. 2000).  The seven hydrophilic loop regions of mouse UCP3 were cloned into a 
pGBKT7 vector containing the GAL4 DNA binding domain which was used as bait 
against a human heart cDNA library.    
2.3 Plasmid DNA Constructs 
Full length mUCP3 and mDCI were amplififed from a mouse heart cDNA library.  
These fragments were cloned into a pcDNA3.1 vector with V5 tag or pcDNA6 vector 
with myc or GFP tag, respectively (Invitrogen, Carlsbad, CA).   
2.4 Cell Culture 
HeLa, C2C12, H9C2, FVBC3, and NIH3T3L1 cells were obtained from the 
American Type Culture Collection (ATCC, Manassas, VA).  All cells were cultured in 
Dulbecco‟s Modified Eagle Medium containing 10% FBS and 1% 100X PenG-
Streoptomycin (Invitrogen, Carlsbad, CA) with 5% CO2 at 37°C.  Transient transfections 
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were performed using either Fugene HD reagent (Roche Applied Sciences, Indianapolis, 
IN) or Lipofectamine (Invitrogen, Carlsbad, CA) per the manufacturer‟s instructions.  
Cells were incubated for 24 or 48 hours prior to treatments or experiments. 
2.5 Immunoblotting 
Cell or tissue lysates were prepared in RIPA buffer (50mM Tris-HCl, 1% NP-40, 
0.5% Sodium Deoxycholate, 0.1% SDS, 150mM NaCl, 2mM EDTA, pH 8.0).  The 
Pierce bicinchoninic acid assay (Pierce Biotechnology, Rockford, IL) was used for 
protein quantitation.  Samples were then prepared for SDS-PAGE with 4X sample 
(250mM Tris-HCl, 8% SDS, 40% glycerol, 8% β-mercaptoethanol, 0.02% bromophenol 
blue) and separated on 10 or 12% gels.   Proteins were then transferred to nitrocellulose 
or PVDF membranes and probed with primary antibodies per the manufacturer‟s 
instructions; mouse monoclonal anti-myc (Cell Signaling, Danvers, MA), rabbit 
polyclonal anti-V5 (Abcam, Cambridge, MA), mouse monoclonal anti-GFP (Invitrogen, 
Carlsbad, CA), ADRB3 goat polyclonal (Santa Cruz Biotechnology, Santa Cruz, CA).   
Custom antibodies were generated for mUCP3 and mDCI (Washington Biotechnology, 
Columbia, MD) and used at a concentration of 1:500 in 5% milk for 16 hours at 4°C.  
Secondary antibodies were sheep anti-mouse and donkey anti-rabbit (Amersham, 
Pescataway, NJ) or donkey anti-goat (Santa Cruz Biotechnology, Santa Cruz, CA).  
Membranes were then developed using Super Signal West Pico or Super Signal West 





Protein lysates of 100µg were prepared in 300 µL of immunoprecipitation buffer 
(RIPA or 1% Triton X-100 in PBS).  Samples were incubated with either 2µg of primary 
antibody or IgG for controls at 4°C for 16 hours with rotation.  Protein A/G Sepharose 
beads (30µL) were added to each sample and then rotated for 4 hours at 4°C.  Beads were 
then washed in high-stringency immunoprecipitation buffer (1% Triton X-100 in PBS or 
RIPA with 600mM NaCl) and prepared for SDS-PAGE as described above.  For samples 
that were cross-linked, we used the method of Thompson et al. (Thompson and Kim 
2004) with the following modifications; the plasma membrane permeable crosslinker 
DSP (Pierce Biotechnology, Rockford, IL) was applied to cells at a concentration of 
1mM per manufacturer‟s instructions.  The crosslinking reaction was stopped with the 
stop buffer (1M Tris, pH 7.5).  Each immunoprecipitation was repeated three times and 
figures show representative western blots. 
2.7 Recombinant Protein Purification  
Full-length mUCP3 was cloned into the pGEX-6P-1 vector with GST tag (GE 
Healthcare, Piscataway, NJ).  Mouse DCI without the MTS was cloned into the pET-21b 
vector with 6XHis tag (mDCI∆MTS-6XHis) (Novagen, Madison, WI).  Vectors were 
transformed into the competent BL21 (DE3) pLysS E. Coli strain and placed into a 37°C 
shaking incubator at 220 rpm.  After reaching an OD of 0.3 (measured at 600nm), protein 
expression was induced by adding 1mM IPTG and returning the transformed bacteria to 
the shaking incubator for either 3 hours at 30°C (for pGEX-6P-1) or 3 hours at 37°C (for 
29 
 
pET-21b).  The cells were then harvested by centrifugation at 8000xG for 10 minutes and 
stored at -80°C.  Mouse UCP3 was diverted to inclusion bodies which required 
processing as previously described (Jaburek and Garlid 2003).  Mouse UCP3 inclusion 
bodies were purified on a GSH column and DCI was present in the soluble fraction which 
was purified using a Nickel-NTA column (Qiagen, Valencia, CA). 
2.8 GST Pulldowns 
Purified glutathione S-transferase protein or GST-mUCP3 fusion protein (15µg) 
was prebound to glutathione-Sepharose 4 Fast Flow beads (GE Healthcare, Piscataway, 
NJ) in GST assay buffer (PBS with 600mM NaCl) then rotated for 16 hours at 4°C.  
After rotation, the beads were washed four times in GST assay buffer then incubated 
either alone or with 300ng mDCI∆MTS-6XHis.  After incubation the beads were washed 
with GST assay buffer eight times and prepared for SDS PAGE.  The pulldown assay 
was repeated three times and the figure shows a representative western blot and 
coomassie stained gel.  
2.9 Isolation of Mouse Tissues 
Mice were sacrificed via CO2 asphyxiation and tissues were immediately 
harvested and placed in ice-cold CP-1 buffer (100mM KCL, 50mM Tris-HCl, 2mM 
EGTA, pH 7.4).   
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2.10 Isolation of Mitochondria  
Tissues were finely minced in CP-1 buffer than transferred to a 30mL glass 
Potter-Elvehjem homogenizer.  After 60 manual strokes, the homogenates were 
centrifuged at 500g then applied to a 40µm cell strainer to remove intact cells.  The 
filtrates were then spun at 10,600g in microcentrifuge tubes to pellet the mitochondria.  
The pellets were resuspended in the appropriate lysis buffer for subsequent experiments.       
2.11 Quantitative RT-PCR 
Tissue or cells were harvested as described above and total RNA was isolated 
using TRIzol
®
 reagent (Invitrogen, Carlsbad, CA).  RNA was converted to cDNA per 
manufacturer‟s instructions using SuperScript II Reverse Transcriptase (Invitrogen, 
Carlsbad, CA).  Sample cDNA was then amplified using iTaq SYBR Green Supermix 
with ROX (Bio-Rad Laboratories, Hercules, CA) and measured using a CFX96 Real-
Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA).  Primers used were; 
mUCP3 sense 5‟- ACTATGGATGCCTACAGAACC-3‟ antisense 5‟-
GACCCGATACATGAACGCT-3‟, mDCI sense 5‟-CAGAGACTGCCCAAGGTCAT-3‟ 
antisense 5‟-TGGCGTCCTTATCTTGGAAC-3‟, GAPDH sense 5‟-
AGAACATCATCCCTGCATCC-3‟ antisense 5‟-GGTCCTCAGTGTAGCCCAAG-3‟.  
Cycling conditions were initial denaturing 95 for 3 minutes, then 40 cycles of 95°C for 
15 seconds and 55°C for 30 seconds.  Analyses were repeated three times and data 
represent fold change relative to levels of GAPDH. 
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2.12 Mitochondrial Sublocalization Assay 
We utilized the method of Whatcott et al. (Whatcott, Meyer-Ficca et al. 2009) 
with modifications.  Briefly, mouse heart mitochondria were isolated as described above.  
Water soluble digitonin (MP Biomedical, Cleveland, OH) was used for permeabilization.  
After proteinase K treatment, the protease inhibitor PMSF was added at 2mM 
concentration to stop the reaction.  Mitochondrial subcompartment marker antibodies 
used were as follows; anti-mitofusion, anti-aconitase (Abcam, Cambridge, MA) and anti-
Cyt. C (Santa Cruz Biotechnology, Santa Cruz, CA).  This assay was repeated three times 
and the figure shows a representative western blot. 
2.13 Fluorescence Microscopy 
For mitochondrial staining, the membrane potential sensitive dye TMRM was 
used.  Live cells were stained with 25nM TMRM for 30 minutes at 37°C then washed 
three times with PBS.  For nuclear staining, DAPI (Pierce Biotechnology, Rockford, IL) 
was used at a concentration of 50µg/mL.  Equipment used for measuring mitochondrial, 
nuclear, and GFP fluorescence was; Nikon Eclipse Ti-S microscope, 60x Nikon Plan Apo 
VC Oil objective with numerical aperture 1.40, and a Photometrics Coolsnap EZ camera.  
Images were processed using Nikon NIS elements BR 3.0 Software.  Each assay was 




2.14 Myocyte Oxygen Consumption 
Skeletal muscle cell respiration rates were quantified using a Clark-type electrode 
(Insetech Laboratories, Plymouth Meeting, PA).  Two million cells per sample were 
added to the 1mL chamber containing either HBSS (for glucose controls) or HBSS with 
100µM water soluble oleic acid.  The rate of oxygen consumption was obtained from 
linear regions of the slope observed with each treatment for three independent samples.  
Each assay was repeated three times and the figures shows mean oxygen consumption 
rates. 
2.15 Primary Cell Isolation 
We followed the method of Ojima et al. (Ojima, Uezumi et al. 2004).  Skeletal 
muscle was removed from recently-sacrificed mice and minced in sterile, ice-cold PBS.  
The tissue was then digested in PBS with 10% FBS and 0.2% type II collagenase 
(Worthington Biochemical, Lakewood, NJ).  After digestion, the tissues were filtered 
through 100µm and 40µm cell strainers.  Samples were then spun at 800g for 5 minutes 
and the pellets were resuspended in hypotonic buffer (0.17M Tris-HCl Ph7.65: 0.83% 
NH4Cl = 1:9 (V/V)).  After 30 seconds, the suspended cells were diluted with 10mL PBS 
and spun at 800g for 5 minutes.  The pellet was resuspended in growth media (HamF10 





2.16 Bi-molecular Fluorescence Complementation 
We used the Venus technology originally developed by Hu and colleagues (Shyu, 
Liu et al. 2006) which uses two vectors, each containing one half of the GFP protein.  
When the two halves come into close proximity, the GFP protein will be created and 
fluoresce.  The Venus vectors pBiFC-VN173 and pBiFC-VC155 were obtained from the 
Addgene repository (Cambridge, MA).  The N-terminal (amino acids 1-172) half of the 
GFP protein was subcloned into the pcDNA6mDCI-myc plasmid.  The C-terminal 
(amino acids 155-238) of GFP were subcloned into the pcDNA3.1mUCP3-V5 (full 
length with C terminus in intermembrane space) and pcDNA3.1mUCP3∆Ct-V5 (with C 
terminus in mitochondrial matrix).  The resulting fusion proteins were imaged by 
microscopy as previously described or on a Beckman-Coulter EPICS XL flow cytometer.  
Each assay was repeated three times and the figures show representative images. 
2.17 Fatty Acid Oxidation 
We employed the method of Mao et al. (Mao, Kraus et al.).  H9C2 cells were 
grown in a 24-well plate then transiently transfected with the indicated plasmids.  The 
transfected myotubes were placed in serum-free DMEM for 2 hours prior to changing to 
pre-incubation media (DMEM, 0.25mM oleate, 12mM glucose, 4mM glutamine, 25mM 
HEPES, 1% fatty acid free BSA) for one hour.  Radiolabeled oleate or palmitate 
(American Radiolabeled Chemicals, St. Louis, MO) was added at a concentration of 
1µCi/mL and the wells were immediately covered with filter paper.  The cells were 
incubated for 1.5 hours at 37°C then the filter paper covering the wells was saturated with 
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3M NaOH and the cells were lysed with the addition of 70% perchloric acid.  The 
radioactivity collected in the filter paper was measured via scintillation counting.  Each 
sample was performed in triplicate and the assays were performed three times. 
2.18 Animals 
C57Bl6/J, B129, and FVB wild type mice were obtained from Jackson 
Laboratories (Bar Harbor, ME).  C57Bl6/J UCP3 -/- mice were a gift of Dr. Marc 
Reitman, formerly of the National Institutes of Health.  C57Bl6/J-hUCP3-α1actin-SKM-
TG+/+ mice were a gift of Dr. Mary-Ellen Harper of the University of Ottawa.  FVB-
UCP1-DT mice were generated by Dr. Brad Lowell of Harvard University and obtained 
from Jackson Laboratories (Bar Harbor, ME).  C57Bl6/J UCP1 -/- mice were a gift of Dr. 
Leslie Kozak of the Pennington Biomedical Research Institute.  Animals were maintained 
on Prolab RMH 2000 5P06 chow and a 12 hour light/dark cycle.  All procedures were 
approved by the University of Texas Institutional Animal Care and Use Committee 
(IACUC). 
2.19 Intraperitoneal Temperature Probe Placement 
The surgery was performed under sterile technique.  Briefly, mice were given 
preoperative injections of 5mg/kg carprofen then the right dorsal flank was shaved and 
cleaned with sterile povidine solution.    Isofluorane was administered via nose cone and 
after onset of general anesthesia a transverse oblique incision was made dorsally above 
the iliac crest.  A similar incision was then made in the peritoneal wall and the wireless 
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temperature probe was inserted unanchored into the peritoneal cavity.  The peritoneal 
wall incision was closed with nonabsorbable Vicryl sutures.  The skin was closed with 
sterile skin staples.  Animals were observed for signs of distress or infection for 72 hour 
prior to experiments.      
2.20 Thermogenic Drug Administration 
Male or female mice (~8 weeks of age) weighing between 20-25 grams were used 
for all studies.  After a 48 hour recovery period, mice were moved to a temperature-
controlled environment @ 25°C with ad libitum access to food and water.  Mice were 
weighed and baseline temperatures recorded prior to subcutaneous administration of 
methamphetamine (25mg/kg), norepinephrine (1mg/kg) or lipopolysaccharide (25ng/kg) 
dissolved in vehicle (sterile water for injection). All doses were administered 
subcutaneously on the dorsal aspect of the animal sufficiently distant from surgical 
wounds.   
2.21 Surgical Denervation of Intrascapular BAT 
We used the method of Bartness & Wade (Bartness and Wade 1984) that was 
adapted from Foster and colleagues (Foster, Depocas et al. 1982) . Animals were 
prepared for surgery as described above.  A transverse incision was made distally to the 
IBAT on the dorsal surface of the mouse in order to expose the subcutaneous fat layer. 
This layer of white fat was retracted to expose the two lobes of the IBAT pad. One 
incision was made on each lateral surface of IBAT pad in order to sever the 5 intracostal 
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nerves leading into the tissue.  The skin was then closed with sterile skin staples.  
Animals were observed for signs of distress or infection for 72 hour prior to experiments.      
2.22 Statistics 
Statistical evaluation of qRT-PCR, western blotting, and FAO data was performed 
using the student‟s t-test with significance set a priori at p<0.05.  Data represent averages 
with error bars representing standard error of the mean (SEM) from at least 3 independent 
experiments.  For each experiment which assessed change in core body temperature, two 
groups were compared (experimental vs. control).   A repeated measures analysis of 
variance (ANOVA) was performed to determine difference between the means of the two 
groups with significance set a priori at p<0.05.  A post-hoc Student Newman-Keuls test 
was performed to assess pair-wise comparisons of individual timepoints from baseline.  
For the whole cell oxygen consumption experiment (Figure 3.9), we performed a 2-way 




Chapter 3 – Skeletal muscle UCP3 responds to diverse thermogenic stimuli 
3.1 Introduction 
UCP3 is expressed in skeletal muscle, brown adipose tissue (BAT) and heart (Boss, 
Samec et al. 1997; Gong, He et al. 1997).  Among these tissues, UCP3-dependent 
mitochondrial uncoupling has only been observed in skeletal muscle, the most highly 
metabolic organ in humans – representing 40% of human body mass and 30% of overall 
oxygen consumption.  Hyperthyroidism induces skeletal muscle UCP3 levels and 
temperature responses in humans and animals (Hesselink and Schrauwen 2005), but has 
little effect on BAT thermogenesis or UCP1 expression (Rothwell and Stock 1984; 
Petrovic, Cvijic et al. 2003).  UCP3 in rodent BAT is thought to not mediate significant 
thermogenesis.  BAT thermogenesis is normal in UCP3-deficient mice (i.e. they adapt 
normally to cold) (Nedergaard, Golozoubova et al. 2001), suggesting that UCP3-
dependent heat production in response to amphetamines occurs outside of BAT.    
Previous studies have shown that the amphetamine compound MDMA significantly 
decreases skeletal muscle ATP levels in situ, in vivo, a marker of strong mitochondrial 
uncoupling (Rusyniak, Tandy et al. 2005).  In most if not all cases, except in “Malignant 
Hyperthermia” (see Section 1.2.1. Hyperthermia and Heat Illnesses), thermogenic 
responses to physiologic stimuli (e.g. cold, feeding, infection, thyroid hormone) and 
pathologic stimuli (e.g. thyrotoxicosis, pheochromocytoma) are integrated centrally in the 
hypothalamus and lead to the activation of the sympathetic nervous system (SNS) and 
norepinephrine (NE) release into the bloodstream.  NE primarily binds to β3-
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adrenoreceptors in the endothelial, adipose, and skeletal muscle tissues (Chamberlain, 
Jennings et al. 1999).  Upon activation, β3-ARs mediate the liberation of free fatty acids 
(FFAs) and lead to their accumulation in the adipose tissue, bloodstream, and muscle.  
FAs in the bloodstream are taken up into thermogenic metabolically active tissues such as 
brown fat and skeletal muscle to be used as fuel for work or heat production.   In cells, 
isolated mitochondria, and recombinant purified liposomal systems, FAs have been well 
established to be required for the activation of uncoupling proteins (Garlid, Jaburek et al. 
1998).  The pathway of activation for uncoupling proteins is listed in Figure 3.2.  Thus, 
the goal of this investigation was to determine the anatomy of amphetamine-induced, 
UCP3-dependent thermogenesis (Figure 3.1). 











Figure 3.1  Two Potential Pathways For Amphetamine-Induced UCP3 
Activation.  UCP3 is expressed in brown adipose tissue (BAT) and skeletal muscle.    
Perhaps unlike muscle, BAT contains both the substrates (FAs) and targets (UCPs) 
within the same cell and tissue.  In contrast a novel model is proposed whereby FAs 
originate in the more distant white adipose tissue (WAT) and travel through the 


















Figure 3.2  Timeline of Amphetamine-Induced Thermogenesis.  Administration of 
amphetamines (e.g. methamphetamine, MDMA) causes activation of the sympathetic 
nervous system and release of catecholamines (e.g. norepinephrine, epinephrine, 
dopamine).  Catecholamines bind to their β3-adrenoreceptors on adipose tissue to cause 
liberation of free fatty acids (FFAs).  FFAs are taken up by skeletal muscle and cause 
UCP3 activation and thermogenesis.  The pathway shown above represents the timeframe 








3.2.1 Characterization of C57Bl6/J UCP3 -/- Knockout Mouse 
The C57Bl6/J strain of mouse was used for the pivotal studies that established the UCP3-
dependence for amphetamine-induced hyperthermia (Mills, Banks et al. 2003).  However, 
the selection of this strain has received some criticism.  Two main issues surround the use 
of these mice for temperature studies. (1) Wild-type C57Bl6/j mice are reported to have a 
large deletion in the gene encoding mitochondrial nicotinamide nucleotide 
transdehydrogenase (NNT), a transmembrane protein that transfers hydride ions between 
NADH and NADPH and their oxidized species (Freeman, Hugill et al. 2006). Therefore, 
theoretically, loss of NNT could lead to alterations in mitochondrial redox balance or 
proton motive force across the inner membrane that may augment UCP3 function (i.e. 
render UCP3 supraphysiologically thermogenic). Another possibility is that the loss of 
thermogenesis in the UCP3 null strain stems from a synthetic defect due to the combined 
deletion of both NNT and UCP3 genes. We confirmed the deletion (exons 7 thru 11) of 
the NNT gene in our C57Bl6/j WT and UCP3 null mice, and that wild type NNT is 
present in B129 mice (Figure 3.3 A-B). (2) The loss of thermogenesis in UCP3-null mice 
could result from artifacts pertaining to the methodology used for UCP3 gene targeting 
and homologous recombination. For example, the C57Bl6/j UCP3 null strain was 
generated using B129 mouse stem cells that were used for the original gene targeting. 
B129 mice are purported to exhibit a thermoregulatory trait locus for ethanol 
hypothermia approximately 10.5 cM from the UCP3 gene located on 11q13.4 (Crabbe, 
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Belknap et al. 1994). Thus, a thermoregulatory mutation in the B129 strain could, albeit 
highly unlikely given the 10 backcrosses, mediate thermogenic defects unrelated to 
uncoupling protein 3 per se. Ruling out each of these possibilities, we show that B129 
and C57Bl6/j mice have equivalent thermogenic responses to sympathomimetic drugs 
(methamphetamine, METH, Fig. 3.3 C), and have similar levels of skeletal muscle 
(SKM) mitochondrial UCP3 protein (Fig. 3.3 D). Figure 3.3 C shows that METH (20 mg 
/ kg) induces overlapping body temperature responses in these different strains of mice.  
The experiment in Fig. 3C, and those in published work in rats, indicates that different 
rodent species and mouse strains respond to diverse sympathomimetic agents with highly 
similar thermogenic responses in terms of magnitude and time course changes in body 
temps. Thus, the UCP3 phenotype first established (Mills, Banks et al. 2003) is robust, 
and is independent of mouse strain and rodent species. Another important issue with 
regard to the phenotypes observed in the sympathomimetic-induced thermogenesis 
models deals with whether or not the effects are direct in terms of activation of UCP3, or 
are indirectly mediated by the activation of the sympathetic nervous system (SNS). The 
amphetamine MDMA has no direct uncoupling effects on muscle mitochondria 
(Rusyniak, Tandy et al. 2005), but rather appears to mediate its actions indirectly through 
activation of the SNS. In addition, the structurally distinct sympathomimetic 
amphetamine drugs 3,4-methylenedioxymethamphetamine and methamphetamine 
(MDMA, METH) induce similar patterns of thermogenesis in C57Bl6/j mice and UCP3-
null mice are similarly protected from METH and MDMA hyperthermia (Sprague, 












Figure 3.3  Loss of Sympathetic Hyperthermia in C57Bl6/J UCP3-/- Mice is Not a 
Strain Effect.   A, C57Bl6/j mice have a large deletion mutation between exon 7 
through exon 11 in the NNT gene indicated by arrows.  B, RT-PCR (skeletal muscle 
mRNA) with primers to amplify from exon 6 thru 12 showing truncated NNT mRNA 
species in C57Bl6/j WT and UCP3 null mice, but a normal sized NNT mRNA fragment 
in B129 mice. C, B129 and C57Bl6/j mice (6-8 weeks) have identical sympathomimetic-
induced (METH, methamphetamine, 20 mg/kg, s.c.) thermogenic responses (wireless 
temperature telemetry) over time (minutes). No significant difference was observed 
between groups (N=4) at any time point. D, Immunoblot shows similar amounts of UCP3 
protein in isolated skeletal muscle mitochondria from B129 and C57Bl6/j mice. UCP3 -/- 
mitochondrial lysates are shown as an antibody control, and mitochondrial DNA 
polymerase gamma (DP-gamma) is shown as a loading control. E, densitometric analysis 














3.2.2 Generality of UCP3 in Thermogenic Responses 
If UCP3 activation by MDMA and METH results from the sympathomimetic 
action of the drugs, then NE levels should increase prior to peak thermogenesis. 
Additionally, NE administration should elicit a decreased metabolic response in UCP3 
knockout vs. WT mice. If UCP3 activation by METH / MDMA is physiologically 
relevant to thermoregulation in general, UCP3-null mice should exhibit a similarly 
diminished metabolic response to the bacterial pyrogen lipopolysaccharide. Recent data 
published in Cell Metabolism show that mice deficient in the prototypic UCP1 have only 
a modest, roughly 30% metabolic defect (oxygen consumption) in response to systemic 
administration of NE (1 mg/kg, sc) under normal dietary conditions (Feldmann, 
Golozoubova et al. 2009). Along with our preliminary and published observations, these 
data strongly support the notion that a significant, alternative thermogenic pathway exists 
that is UCP1-independent. We have published that levels of NE sharply increase (35-
fold) in the bloodstream of rats 30 min. prior to peak MDMA-induced hyperthermia (60-
90 min.) and that blockade of noradrenergic receptors (α1 + β3-adrenoceptor, AR) fully 
blocks hyperthermia induced by MDMA and METH (Sprague, Mallett et al. 2004; 
Sprague, Moze et al. 2005). As shown in Feldmann et al., 2009, in response to NE 
administration (1 mg / kg, sc), C57Bl6/j UCP3-null mice exhibit a large blunting (by 
roughly 70%) of peak (20 min.) of thermogenesis compared to WT (Fig. 3.4A). Using the 
bacterial pyrogen lipopolysaccharide (LPS), UCP3-null mice also show abrogated 
endotoxin-mediated fever (Fig. 3.4B). These experiments establish the physiologic 
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relevancy of both the sympathomimetic thermogenesis model and of UCP3 in 









Figure 3.4. UCP3 knockout mice (C57Bl6/j UCP3 -/-) exhibit blunted thermogenesis 
to physiologic fever mediators.  (a) WT and UCP3 KO mice (N = 4) were administered 
norepinephrine (NE, 1mg/kg, sc). WT mice exhibited a rapid and significant (P < 0.05, 
indicated by asterisks) peak increase over baseline in core body temperature at 20 
minutes post injection. UCP3-null mice did not exhibit significantly increased body 
temperature from baseline at any time point. (b) WT and UCP3 -/- mice were 
administered the bacterial endotoxin lipopolysaccharide (LPS, 25ug/kg, sc). WT mice 
displayed a significant (p < 0.05, indicated by asterisks) febrile response over baseline, 
whereas UCP3 KO mice failed to generate a significant thermogenic response over the 
entire time course, and often develop significant hypothermia.  A repeated measures 
analysis of variance (ANOVA) was performed to determine difference between the 
means of the two groups with significance set a priori at p<0.05.  A post-hoc Student 
Newman-Keuls test was performed to assess pair-wise comparisons of individual 




3.2.3 Involvement of BAT in METH thermogenesis 
Brown adipose tissue (BAT), although typically studied for its presence of UCP1 and 
strong contribution to cold-induced thermogenesis, also expresses UCP3.  Thus, the 
UCP3-dependent phenotypes seen with certain genotypes cannot be assigned to solely 
one UCP3-expressing tissue.  In this regard, the investigation into the tissue principally 
responsible for UCP3-dependent thermogenesis is crucial.  Given the importance of BAT 
for cold-induced thermogenesis, it seems plausible that it is also responsible for 
responding to other types of thermogenic stimuli.  If as hypothesized, the model (Figure 
3.1) is correct that UCP3 in muscle is the anatomic site of sympathomimetic 
thermogenesis, then BAT ablation should have little or no effect on a UCP3-driven 
response. Figure 3.5 shows that METH induced heat production is modestly induced in 
mice bearing with partially (~70%) ablated BAT (FVB/N mice that express a UCP1 
promoter diphtheria toxigene, FVB/N UCP1-DT) compared to wild type FVB/N controls 
(Figure 3.5). BAT ablated mice are also slightly more obese than wild type littermates 
(Figure 3.5).  UCP3 is known to be upregulated in skeletal muscle in response to certain 
stimuli (e.g. fatty acids, PPAR agonists, fasting) (Boss, Samec et al. 1997; Boss, Samec 
et al. 1998).  Skeletal muscles cells treated in vitro with both oleic and palmitic acids 
(C18:1, C16:0, respectively) show robust upregulation (Figure 3.6 Left).  Conversely, 
brown adipocytes subjected to the same conditions show low basal expression levels and 
a lack of UCP3 upregulation in response to fatty acids.  These data strongly support the 





Figure 3.5 Ablation of BAT Does Not Affect Amphetamine-Induced 
Hyperthermia.  Transgenic UCP1-DTA mice (N = 4) with partial (50-80%) ablation of 
brown fat induced by a UCP1-promoter-diphtheria toxigene have increased METH-
induced (20 mg/kg, sc) peak thermogenesis, 30% reduction in total BAT tissue, and 20% 
increased body weight compared to WT mice.  For the assessment of change in core body 
temperature (top graph), a repeated measures analysis of variance (ANOVA) was 
performed to determine difference between the means of the two groups with significance 
set a priori at p<0.05.  No post-hoc test was performed because the difference between 
the two groups was not statistically significant.  Statistical evaluation of BAT Tissue and 
Body Weight (lower panels) was performed using the student‟s t-test with significance 
set a priori at p<0.05.  Data represent averages with error bars representing standard error 
of the mean (SEM) from at least 3 independent experiments.  Shown below the bars in 















             
 
Figure 3.6 Levels of UCP3 in Skeletal Muscle, But Not BAT, are Responsive To 
Fatty Acid Treatment.  Left, Levels of UCP3 mRNA (measured by qRT-PCR) are 
sharply induced in differentiated (5 days) C2C12 (mouse) and L6 (rat) myotubes in 
response to treatments with palmitic acid (C16:0) or oleic acid (C18:1) at 100uM for 24 
hours. Right, UCP3 mRNA levels were unaffected by palmitic or oleic acid treatments in 
differentiated brown pre-adipocytes (FVBC3).  Statistical evaluation was performed 
using the student‟s t-test with significance set a priori at p<0.05.  Data represent averages 
with error bars representing standard error of the mean (SEM) from at least 3 independent 




3.2.3 Skeletal muscle is a dominant site of FA-sensitive, UCP3-mediated 
thermogenesis.  
Brown adipose tissue (BAT) and skeletal muscle (SKM) both express UCP3, and 
are the major metabolic and thermogenic tissues in animals. No evidence suggests that 
BAT UCP3 is thermogenic. As shown in Figure 3.5 above, partial ablation of brown 
adipose tissue has no effect on amphetamine-induced thermogenesis.  In addition, in 
Figure 3.6 above, UCP3 is significantly upregulated in response to fatty acid treatment in 
skeletal muscle, but not brown adipose cells.  To further scrutinize the thermogenic 
capacity of skeletal muscle UCP3, we used mice recently generated by Mary Ellen 
Harper‟s group that modestly (3-5 fold) overexpress UCP3 specifically but at 
physiological levels in skeletal muscle (hemizygous, alpha-1 actin promoter). Using these 
mice, we found that a non-thermogenic dose of METH in wild type C57Bl6/j mice 
induces a thermogenic response over baseline core body temperature in SKM-UCP3 
overexpressing transgenic mice (Figure 3.7).  The mice used in this experiment, do 
however, have intact endogenous UCP3 expression (including in BAT).  In order to 
determine the thermogenic capacity of skeletal muscle UCP3 specifically, these mice 
were crossed with a UCP3 global knockout mouse.  The resulting strain did not express 
endogenous UCP3 in any tissue, but did possess the skeletal muscle specific UCP3 
expression at physiologic levels.  In response to methamphetamine administration, these 
UCP3-/- SKM-UCP3 mice showed a hyperthermic response that was significantly higher 













Figure 3.7 Skeletal Muscle Specific UCP3 Overexpression Augments 
Thermogenic Response to Amphetamines.  Transgenic mice (N = 4) overexpressing 
UCP3 specifically in muscle (3-5 fold overexpression) show a detectable rise in body 
temperature over baseline to a non-thermogenic dose of METH (5mg/kg s.c.) that fails to 
induce thermogenesis in WT mice.  A repeated measures analysis of variance (ANOVA) 
was performed to determine difference between the means of the two groups with 
significance set a priori at p<0.05.  No post-hoc test was performed because the 














Figure 3.8 Absence of BAT UCP3 Does Not Prevent Amphetamine-Induced 
Thermogenesis.  Transgenic mice overexpressing UCP3 specifically in muscle (3-5 fold 
overexpression) were crossed with UCP3 global knockout mice (N = 4).  The presence of 
UCP3 in skeletal muscle only rescues the loss of effect METH (20 mg/kg, sc) seen in 
UCP3 knockout animals.  * indicates significantly different from WT (p < 0.05).  A 
repeated measures analysis of variance (ANOVA) was performed to determine difference 
between the means of the two groups with significance set a priori at p<0.05.  A post-hoc 
Student Newman-Keuls test was performed to assess pair-wise comparisons of individual 













Figure 3.9 FFA Released From WAT Activate Skeletal Muscle UCP3.  
Differentiated white adipocytes were treated with either vehicle (CNTRL) or 
isoproterenol to stimulate lipolysis (WAT).  The conditioned media was then applied to 
wild-type (WT) or UCP3 knockout (KO) skeletal muscle cells and thermogenesis was 
measured by indirect calorimetry using a respiration chamber fitted with a Clarke-type 
electrode (Instech labs).  WAT but not CNTRL treated wild-type cells showed increased 
UCP3-dependent respiration.  UCP3 knockout cells did not show a change after the 
addition of WAT versus CNTRL conditioned media.  A 2-way ANOVA with 
significance set a priori at p<0.05 was used to compare WT-CNTRL to WT-WAT and 






physiological concentrations is a thermogenic mediator. Consistent with a role for fatty 
acids in the response specifically in muscle, we isolated primary myoblasts from wild 
type and UCP3-null mice and differentiated cells for 5 days in low serum conditions 
(which induces UCP3 in WT cells, Figure 4.5 Left). Oleic acid-induced thermogenesis is 
significantly decreased in UCP3 knockout cells compared to WT (Figure 4.13 B).  
Although the direct application of fatty acids to skeletal muscle cells was able to activate 
UCP3, we also sought to determine if fatty acids released from white adipose tissue had a 
similar effect.   We differentiated white adipocytes in vitro, then treated with either 
isopreterenol (3µM) or vehicle to stimulate lipolysis.  The free fatty acid-containing 
conditioned media was harvested and used for skeletal muscle cell oxymetry (Figure 3.9).  
The WAT-conditioned media was able to induce uncoupled thermogenesis (as measured 
by indirect calorimetry) in skeletal muscle cells similar to treatment with fatty acids 
directly.  UCP3 was required for this activation, as UCP3 knockout cells did not have an 
uncoupled respiration response to the WAT-conditioned media.      
3.3 Conclusions 
Brown fat (BAT) uncoupling protein 1 (UCP1) is the only established mediator of 
sympathetic nervous system-mediated heat generation in mammals. However, the low 
abundance of BAT and UCP1 in adult humans raises questions about its metabolic 
significance and clinical potential. The canonical view of thermogenic physiology was 
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built largely on the cold-induced, BAT thermogenesis pathway in rodents. As depicted in 
Figure 3.10, in response to cold, hypothalamic SNS activation leads to the release of  
 
 
Figure 3.10  Canonical vs. novel UCP-dependent thermogenesis.  The canonical 
pathway of UCP thermogenesis is based upon brown adipose tissue (BAT) which 
contains both the substrates (FAs) and targets (UCPs) within the same cell and tissue.  In 
contrast a novel model is proposed whereby FAs originate in the more distant white 





norepinephrine (NE) from sympathetic nerves that richly innervate BAT. In turn, NE 
binds and activates plasma membrane beta adrenergic receptors (β-AR) on BAT 
adipocytes, leading to the activation of lipases that catalyze the liberation of fatty acids 
(FA) from triglycerides. FAs in turn are transported to mitochondria, where they bind 
UCP1 and activate thermogenesis. In this system, both the substrate for (FA) and the 
mediator of (UCP1) thermogenesis co-exist in the same cell (reviewed in (Nedergaard, 
Golozoubova et al. 2001)). We and others have observed that another SNS-induced 
thermogenesis pathway likely exists. First, UCP1 knockout mice lose only a small, albeit 
significant portion of the thermogenic response to NE administration compared to wild 
type (Feldmann, Golozoubova et al. 2009). UCP3 knockout mice exhibit a larger blunting 
of both sympathomimetic- (synthetic amphetamines) and norepinephrine-induced 
thermogenesis compared to their wild type littermates (Mills, Banks et al. 2003).  
Similarly, UCP3 is an important thermogenic target of thyroid hormone-induced body 
temperature regulation in muscle (Flandin, Donati et al. 2005; Sprague, Yang et al. 2007). 
Finally, it was recently demonstrated that systemic administration of sympathomimetic 
agents blunts brown fat thermogenesis (Rusyniak, Ootsuka et al. 2008).  Based upon 
these observations and the data above, we propose that an alternative, novel pathway of 
thermogenesis exists wherein white adipose and skeletal muscle UCP3 participate in the 
thermogenic responses to sympathomimetic drugs (e.g., methamphetamine, METH) and 
the bacterial pyrogen lipopolysaccharide (LPS, Fig. 3.4 B). In this model, increased 
levels of circulating NE activate β-AR on white adipocytes, leading to the production of 
thermogenic FA and their release into the bloodstream (via the FAT/CD36 FA exporter 
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in white adipocyte plasma membranes). In turn, FAs are imported into skeletal muscle 
(via FAT/CD36 and FATP1 transporters), where they fuel UCP3-dependent 
thermogenesis.  This proposed model is based upon the following observations; 1) 
Hormonal and genetic approaches to selectively increase UCP3 in skeletal muscle 
augemtn sympathomimetic-mediated thermogenesis. 2) Partial ablation (70%) of brown 
fat, a cold-activated thermogenic organ where UCP3 is also expressed, had no effect 
onsympathomimetic-mediated heat generation. 3) Fatty acid-induced thermogenesis (by 
indirect calorimetry) in muscle cells was significantly blunted in UCP3-null compared to 











 Dienoyl-CoA  Isomerase to Augment 
Unsaturated Fatty Acid Oxidation 
4.1 Introduction 
     Derangements in human energy balance involving an interaction between genes and 
environment contribute significantly to metabolic disease and likely underlie the recent 
epidemic of obesity, metabolic syndrome, and diabetes.  At the cellular level, energy 
balance is regulated primarily though the oxidation of energy consumed in mitochondria, 
and the storage of energy not combusted as fat, protein, glycogen, etc.  Mitochondrial 
respiration operates as a balance between substrate availability and energy requirements.  
Mitochondria generate energy by using a proton gradient to convert ADP and oxygen to 
ATP and water.  Excess energy consumed relative to energy used (combusted, or spent) 
leads to obesity and its sequelae.  The development of insulin resistance, particularly in 
skeletal muscle, has been reported as a major factor leading to the development of 
diabetes mellitus.   
     UCP3 regulates energy balance mechanisms in skeletal muscle and alteration of its 
function is linked in numerous clinical studies to obesity and diabetes in susceptible 
populations (Argyropoulos, Brown et al. 1998; Schrauwen, Xia et al. 1999; Schrauwen, 
Xia et al. 1999; Harper, Dent et al. 2002; Liu, Liu et al. 2005; Hsu, Niu et al. 2008).  
Mice lacking UCP3 exhibit increased oxidative stress and accumulation of fatty acids 
(Brand, Pamplona et al. 2002).  Conversely, mice with a 2-5 fold increased UCP3 
specifically in skeletal muscle are protected from diet-induced obesity and insulin 
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resistance (Choi, Fillmore et al. 2007).  However, the mechanism behind this remains yet 
to be defined.  Studies using genetic models of UCP3 overexpression have found an 
effect on metabolism of FAs and mitigation of ROS (Bezaire, Spriet et al. 2005).  Several 
theories have been proposed to explain these effects.  The most widely-held hypotheses 
for UCP3-dependent increased FAO are those originally proposed by Schrauwen 
(Schrauwen, Hoeks et al. 2006) and Harper (Himms-Hagen and Harper 2001), which 
support a model of extrusion of anionic fatty acids or lipid peroxides from the 





 dienoyl-CoA  isomerase (DCI) catalyzes the movement of protons along 
the fatty acid side chain to move double bonds in unsaturated fatty acids from odd to even 
positions to permit their normal beta oxidation to acetyl Co-A  in both peroxisomes and 
mitochondria (Filppula, Yagi et al. 1998).  Unsaturated fatty acids with odd numbered 
double bonds comprise an indispensable group of nutrients such as linoleic and linolenic, 
the essential fatty acids which are required for formation of arachidonate.  Another DCI 
substrate, oleic acid is the principal fatty acid in olive oil, a major constituent of the 
human diet.  Enoyl-CoA metabolites formed from these unsaturated FAs require auxiliary 
enzymes, such as DCI, in addition to the four primary beta oxidation enzymes (Luthria, 
Baykousheva et al. 1995; Shoukry and Schulz 1998; Gurvitz, Wabnegger et al. 1999).  
Accumulation of these metabolites poses a danger to the organism by exhausting stores 
of Co-A (Shoukry and Schulz 1998).   Bacteria, which do not express DCI, must prevent 
accumulation of unmetabolizable enoyl-CoA species through export of the fatty acids 
into their growth medium.  When permitted to accumulate in bacteria, these metabolites 
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inhibit normal beta oxidation (Ren, Aguirre et al. 2004).   Likewise, knockout studies in 
C. Elegans have shown an increase in total fat content in the absence of DCI (Van Gilst, 
Hadjivassiliou et al. 2005).   
Here we describe a novel protein-protein interaction between UCP3 and the 
auxiliary FAO enzyme DCI.  In contrast to previous reports on UCP3 binding partners 
which have occurred outside the protein‟s terminal subcellular compartment (Pierrat, Ito 
et al. 2000), the UCP3-DCI complex exists in the mitochondrial matrix.  DCI is present in 
each tissue that expresses UCP3 (skeletal muscle, heart, brown adipose tissue), and the 
UCP3-DCI complex forms at endogenous protein levels.  The strength of binding was 
augmented with treatment with the DCI substrate oleate.  Likewise, the UCP3-DCI 
complex increased oxidation of oleate.    Mutational analysis of UCP3 and DCI revealed 
a consensus DxxK domain is necessary for binding and the effects on fatty acid 
oxidation.   
4.2 Results 
4.2.1 Interaction of UCP3 and DCI 
     Identifying binding partners for membrane integrated proteins can prove difficult 
because some domains may not be accessible when in its native, folded state.  To combat 
this problem, the 7 hydrophilic domains of mouse UCP3 were used as probes (Figure 
4.1).  Hydrophilic domain 5 was excluded as reliable bait due to substantial false positive 







 dienoyl-CoA  isomerase (DCI) as a potential binding partner for hydrophilic 















Figure 4.1 UCP3 Domain Structure.  UCP3 structure:  inner mitochondrial 
membrane localized UCP3 contains seven hydrophilic domains (HD1-7) connected by 6 















Figure 4.2 DCI Binds UCP3 Hydrophilic Loops Via Yeast-Two Hybrid.   Growth 
phenotypes of yeast expressing full length DCI and individual UCP3 domains HD1-7 






       DCI is an auxiliary fatty acid oxidation protein that exists in mitochondria and 
perixosomes, both of which are sites of beta oxidation in mammalian cells.  The crystal 
structure of DCI has been studied and 4 primary domains have been identified.  Studies 
performed in rat heart and liver mitochondria have shown the N-terminal ~43 amino acid 
mitochondrial targeting signal is not present within mitochondria and presumably cleaved 
upon import.  The catalytic domain contains the two amino acid residues (E196, D204) 
shown to be necessary for retention of the protein‟s isomerase activity.  DCI is thought to 
exist as a homotrimer with use of the trimerization domain that spans amino acids 249 to 
313.  The C-terminal end of DCI contains the 3 amino acid SKL sequence well-
established as a non-cleavable peroxisomal targeting sequence (Figure 4.3). 
     In order to confirm expression patterns in a variety of tissues, the UCP3-containing 
tissues brown adipose, skeletal muscle, and heart were probed for both proteins (Figure 
4.4).  Liver was also used as negative control.  DCI was found to have a similar 
expression pattern as UCP3.  UCP3 is known to undergo significant upregulation in 
response to skeletal muscle differentiation.  C2C12 mouse skeletal muscle cells were 
analyzed via quantitative real-time PCR and although UCP3 was upregulated levels of 
DCI were relatively unchanged (Figure 4.5). 
     Because the bait constructs used for the yeast two-hybrid analysis included 
hydrophilic domains present on both the matrix and intermembrane space sides of UCP3, 
we performed a mitochondrial sublocalization assay on DCI (Figure 4.6).  Proteinase K 
treatment was used for protein digestion, along with increasing amounts of the membrane 
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permeabilizing detergent digitonin.  With increasing detergent concentrations, the 
proteinase has more access to proteins previously protected by intact membranes.  The 
mitochondrial outer membrane protein mitofusin was digested at a low digitonin 
concentration, whereas the intermembrane space protein Cytochrome C and matrix 
protein Aconitase were digested at much higher levels.  DCI was digested at a similar 














Figure 4.3 Structure of mDCI.  DCI protein contains an N-terminal mitochondrial 
targeting sequence (MTS) followed by its catalytic domain (CAT), trimerization domain 











Figure 4.4   UCP3 and DCI Have An Overlapping Tissue Expression Pattern.  
UCP3 and DCI are co-expressed at similar levels in murine brown adipose tissue (BAT), 
skeletal muscle (SKM), and heart (HRT), but not liver.  Immunoblot shows levels of 






























Figure 4.5 UCP3 and DCI Messenger RNA Expression In Muscle.  Quantitative 
real time RT-PCR of UCP3 and DCI expression over a time course (days) of 
differentiation in C2C12 myotubes.  Transcripts were normalized to GAPDH.  Statistical 
evaluation was performed using the student‟s t-test with significance set a priori at 
p<0.05.  Data represent averages with error bars representing standard error of the mean 












Figure 4.6 Mitochondrial sublocalization of DCI.  Immunoblots show the presence 
of the outer mitochondrial membrane (OMM) protein mitofusin, the intermembrane 
space (IMS) resident cytochrome C (Cyt C), and the matrix (MAT) resident aconitase in 
mitochondria that were untreated or treated with proteinase K (Pro K) (lanes 2-7) and 
increasing concentrations of digitonin (DIG) (lanes 3-7, 0.2 to 1.6 mM DIG). OMM 
mitofusin immunoreactivity was lost with Pro K treatment, whereas IMS cytochrome C 
and matrix (MAT) resident aconitase required increasing digitonin concentrations for 
proteolysis.  DCI was protected from the protease K / digitonin pretreatment to a similar 




4.2.2 Expression and Localization of UCP3 and DCI 
  To check for accurate protein trafficking, the full-length DCI cDNA was cloned into a 
GFP-fusion vector and transiently transfected into HeLa cells (Figure 4.7).  The 
membrane potential sensitive dye TMRM was used for detection of mitochondria for live 
cell imaging.  DAPI stain was used to highlight the nuclear compartment.  Upon overlay, 
the GFP fluorescence of the DCI fusion protein coincides with the red TMRM staining 
indicating that the transfected DCI protein traffics correctly to the mitochondria.  In 
addition, cleavage of the mitochondrial targeting signal and mitochondrial localization 
was also confirmed via mass spectroscopy. 
     Next, we utilized HeLa cells to evaluate the interaction of DCI and UCP3 in 
mammalian cells (Figure 4.8).  Full length mUCP3-V5 and mDCI-myc were transfected 
in equal amounts.  Immuno-precipitation with antibody to myc tag revealed that mUCP3-
V5 binds to mDCI-myc in this overexpression system.  To control for another 
mitochondrial protein, the human adenine nucleotide transporter (hANT-myc) was used.  
Binding to mUCP3 was specific for mDCI and not hANT. 
     To test the binding of the endogenous UCP3 protein to mDCI, C2C12 mouse skeletal 
muscle cells were used (Figure 4.9).  C2C12 cells exist as myoblasts until induced to 
differentiate into myotubes which begin to express UCP3 at Day 3.  C2C12 cells were 
transfected with mDCI-myc and allowed to incubate for 48 hours prior to harvesting.  
Lysates prepared from Day 0 cells, as well as fully differentiated Day 7 cells were used 











Figure 4.7 Fluorescence microscopy of DCI mitochondrial localization.  DCI-GFP 
fusion protein is localized to mitochondria as indicated by overlapping staining with the 

















Figure 4.8 In Vitro Interaction of DCI and UCP3.  Detection of the UCP3:DCI 
interaction in co-transfected HeLa cells.  HeLa cells were transfected with the indicated 
plasmids mUCP3-V5, mDCI-myc, or hANT-myc (bottom).  Lysates were 
immunoprecipitated (IP) with anti-myc antibody or the negative control IgG2A and IP 
reactions were separated by SDS-PAGE and immunoblotted (IB) for anti-V5.  UCP3-V5 
(~36 Kd) was immunoprecipitated by the anti-myc antibody but not by IgG2A in cells 
expressing mDCI-myc (lanes 3-4, upper panel).  As a negative control, myc antibody 
failed to immunoprecipitate mUCP3-V5 from cells coexpressing hANT-myc and 
mUCP3-V5 (~36 Kd, lane 5, upper panel).  Middle panel shows input for mDCI-myc 
























Figure 4.9 UCP3 and DCI Interact at Endogenous UCP3 Levels.  C2C12 cells 
were differentiated for 1-7 days into mature myotubes then transfected with mDCI-myc.  
The upper panel shows endogenous UCP3 protein induction (~34 Kd) in isolated C2C12 
mitochondria over time (days).  (Lower panels) Lysates from day 0 (undifferentiated) and 
day 7 (differentiated) myocytes were immunoprecipitated with anti-myc or control IgG2A 
antibodies.  UCP3 immunoreactivity was immunoprecipitated by anti-myc only in the 












Figure 4.10 UCP3 and DCI Bind Directly In Vitro.  A, Expression, isolation, and 
SDS-PAGE of purified recombinant GST-mUCP3 and mDCIΔMTS-6XHis from BL21 
(DE3) E. Coli.  Arrows indicate GST vector control (lane 1, ~26 Kd), GST-mUCP3 
(Lanes 2, 5, ~60 Kd), and mDCIΔMTS-6XHis (lanes 3-5, ~35 Kd). B, Bacteria were 
transformed with the indicated constructs GST vector only (GST), GST-mUCP3, or 
mDCIΔMTS-6XHis and lysates were incubated with glutathione-coupled sepharose 
beads (beads).  Pulldowns were subjected to SDS-PAGE and immunoblotted with a 
custom-made anti-DCI polyclonal antibody.  As shown, DCI immunoreactivity (~35 Kd) 
was selectively pulled down by GST-mUCP3 (lane 2).   Lane 5 shows the positive 





Only the Day 7 samples successfully immunoprecipitated endogenous UCP3 protein with 
anti myc tag antibody.   
In order to determine if the UCP3 and DCI bind directly or require another protein 
or cofactor that is present in cells, a purified, recombinant interaction system was used.  
Full length mUCP3 was cloned into a pGEX6-P1 expression vector which creates a 
recombinant protein with an N-terminal GST tag.  Because mDCI gets trafficked to the 
mitochondrial matrix, then undergoes cleavage of its targeting signal, it will not 
encounter UCP3 as a full length protein.  Therefore, mDCI without its MTS was cloned 
into a pET21b expression vector to include a C-terminal 6X His tag.  Full length UCP3 
binds DCI in an in vitro, purified recombinant system indicating that direct binding can 
occur (Figure 4.10).   
4.2.3 Mutational Mapping of the UCP3:DCI Binding Domain 
     To investigate the region of UCP3 responsible for DCI binding, we generated 
truncation mutants that lack each of the hydrophilic domains (except HD1).  All 
constructs expressed as fusion proteins with the V5 tag and trafficked correctly to the 
mitochondria (data not shown).  HeLa cells co-transfected with full-length DCI or UCP3 
truncation mutants and then lysates were prepared and subjected to immunoprecipitation 
(Figure 4.11).  While all truncation mutants bound DCI, the construct lacking matrix loop 
2/hydrophilic domain 4 (HD4) exhibited altered binding characteristics.  Notably a slight 
interaction remains in the HD4 UCP3 mutant, suggesting that the conserved DVVK-type 







Figure 4.11 Binding of UCP3 HD truncation mutants to DCI in mammalian cells.  
A, Depiction of the mUCP3-V5 hydrophilic (HD) domain truncation mutant constructs 
used for DCI binding analyses.    B, Cells were co-transfected with DCI-myc and the 
indicated V5 tagged full length UCP3 or UCP3HD mutants as indicated (top).  Lysates 
were immunoprecipitated (IP) with anti-myc antibody and immunoblots (IB) were probed 
with anti-V5.  The mutant lacking central matrix loop HD4 (ΔHD4, upper panel) showed 
strongly decreased binding to mDCI.  Middle panel shows input for DCI-myc, and lower 
panel shows input for UCP3 and UCP3 HD mutants.   
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in DCI:UCP3 binding.  To further scrutinize the residues important for binding, 3 
additional mutants were made each lacking one third of the HD4 domain (Figure 4.12).  
After immunoprecipitation, the HD4A mutant, lacking the domain DVVK of UCP3 
matrix loop 2 had an almost complete abolishment of binding (Figure 4.12).  Sequence 
alignment revealed a similar motif contained within the trimerization domain of DCI at 










Figure 4.12 UCP3 and DCI interact via the first 12 amino acids of the central 
matrix UCP3 loop.  The N-terminal (HD4A), middle (HD4B), and C-terminal (HD4C) 
thirds of UCP3 HD4 were truncated to further localize the UCP3:DCI interaction domain.  
Full length UCP3 or each UCP3 HD4A-C mutant was expressed in cells along with full 
length mDCI.  Immunoprecipitations (as performed in B) show that the HD4A mutant 
poorly binds DCI (upper panel).  Shown also are the inputs for DCI-myc (middle panel) 




4.2.4 Nutrient Sensitivity of the UCP3 – DCI Interaction 
The activation of UCP3 by fatty acids, particularly unsaturated fatty acids has 
been well-established.  The substrates for DCI, likewise, are unsaturated fatty acids, such 
as oleate.  Consistent with these facts, we observed via qRT-PCR the significant 
upregulation of DCI and UCP3 in response to oleate treatment more so than the saturated 
FA palmitate (Figure 4.13 A).  Using wild type and UCP3 knockout primary mouse 
myotubes, we discovered that oleate-induced thermogenesis (indirect calorimetry) is 
largely UCP3-dependent (Figure 4.13 B).  Again using cells isolated from the skeletal 
muscle of WT or UCP3 KO mice, immunoprecipitation was performed after treatment 
with oleate and chemical crosslinking.  When immunoprecipitated with anti-DCI 
antibody, a band is clearly visible in WT but not UCP3 KO lysates probed with anti-
UCP3 antibody (Figure 4.14).  This binding effect was exaggerated after a 16 hour 
treatment with 100µM oleic acid and was not due to substantial protein upregulation. 
In order to test the binding effect in real-time, we utilized Venus bifluorescence 
complementation plasmids obtained via Addgene and submitted by Hu (Purdue 
University).  These vectors each contain one half of the GFP protein which is expressed 
as a fusion protein.  When these two halves (VC and VN) are expressed on other proteins 
which come into close contact, as during binding, they will form a full-length GFP 
protein which will fluoresce.  Two mUCP3 constructs were cloned into the VC plasmid, 
one with the C-terminal tag in the inner membrane space (mUCP3-VC), and another with 
the tag in the mitochondrial matrix (mUCP3∆Ct-VC) (Figure 4.15).  As predicted based 







Figure 4.13 Sensitivity of DCI and UCP3 To Unsaturated Fatty Acids.  A, Real 
time RT-PCR quantifications of UCP3 and DCI mRNA expression in C2C12 muscle 
cells after treatments with bovine serum albumin (BSA), oleate (C18:1) or palmitate 
(C16:0) normalized to GAPDH expression.  B, Oleate-, but not glucose-induced 
thermogenesis (oxygen consumption / indirect calorimetry) is strongly blunted in UCP3 
knockout (KO) compared to wild type (WT) primary differentiated murine myotubes.  
Statistical evaluation was performed using the student‟s t-test with significance set a 
priori at p<0.05.  Data represent averages with error bars representing standard error of 






produced fluorescence when co-expressed with mDCI-VN (Figure 4.15).  To further 
explore the dependence upon fatty acids for binding, we co-transfected cells with 
mUCP3∆Ct-VC and mDCI-VN and subjected the cells to serum-free media  or 
treatments of oleic acid (50µm, 100µM, or 300µM).  Via microscopy, the dose-dependent 
increase in complementation fluorescence is clearly visible (Figure 4.16 A).  Next, BSA 
and 300µM oleate treated samples were subjected to flow cytometry.  A population of 









Figure 4.14 The UCP3 – DCI interaction in primary myotubes is oleate-sensitive.  
WT and UCP3 KO differentiated myotubes were treated with 300 µM oleate (16 hr) as 
indicated (below).  Cell lysates were immunoprecipitated with anti-UCP3 followed by 
immunoblotting for anti-DCI.  Upper panel shows that UCP3 specifically interacts with 
DCI in WT (lane 1, 3) but not UCP3 KO cells (lane 2, 4) in a manner strongly enhanced 
by oleate treatment (lane 3 versus lane 1).  Input controls include immunoblots for anti-








Figure 4.15 The UCP3 – DCI complex is formed specifically in the mitochondrial 
matrix in live cells.  Hela cells were transfected with the indicated bimolecular 
fluorescence complementation probes containing N (VN) and C (VC) terminal tag split 
Venus GFP fluorophore fusion proteins with full length UCP3 (mUCP3-VC), a UCP3 
truncation mutant that localizes the tag into the matrix (mUCP3∆Ct-VC), or full length 
DCI (DCI-VN).  Cells were nuclear counterstained with DAPI.  As shown in the lower 
right panel, only cells expressing mUCP3∆Ct-VC and mDCI-VN exhibited fluorescence 









Figure 4.16 The UCP3:DCI interaction is increased by oleic acid in live cells.  A, 
Cells cotransfected with mDCI-VN and mUCP3∆Ct-VC show increased mitochondrial 
GFP fluorescence complementation upon treatment with the indicated doses of oleate 
compared to the negative control BSA.  Shown in A are fluorescence micrographs.  B 
shows flow cytometric evaluation of the distribution of fluorescence.  Clearly visible is 




4.2.5 Functional Impact of the DCI – UCP3 Complex on Fatty Acid Metabolism 
     Previous studies showed that expression of DCI had no effect on mitochondrial 
membrane potential when overexpressed alone and no additive effect when coexpressed 
with UCP3 (data not shown).  To investigate the effect on DCI activity, we employed an 
assay developed by Dong and colleagues (Mao, Kikani et al. 2006) using radiolabeled 
oleic acid to measure fatty acid oxidation.  We used H9C2 heart myocytes because heart 
cells have very few peroxisomes compared to skeletal muscle.  Therfore, transfected 
mDCI would likely shuttle to the mitochondria when transfected.  When mDCI was 
overexpressed, no increase in FAO was seen and although mUCP3 produced an 8% 
increase above controls, this difference was not statistically significant.  When both 
mDCI and mUCP3 are overexpressed, there is a synergistic increase in FAO above 
vector-transfected controls (Figure 4.17 A).  This increase is not observed when a 
saturated fatty acid such as palmitate is used as the sole substrate (Figure 4.17 B).    
     Finally, to determine if the DxxK motifs in either UCP3 or DCI have an effect on 
binding or FAO, we generated the deletion mutants mUCP3∆HD4A and mDCI∆DIIK.  
Immunoprecipitation with IgG control, as well as each wild type protein showed that 
deletion of either the DxxK in UCP3 or DCI was sufficient to abolish binding (Figure 
4.18).  As anticipated, the augmentation of FAO when both UCP3 and DCI are 
overexpressed was completely abolished with the deletion of either DxxK motif (Figure 
4.19).  Surprisingly, overexpression of both DxxK mutants showed a decreased level of 
FAO below wild-type controls, indicating that these mutants may act as dominant 
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Figure 4.17 The UCP3 – DCI complex synergistically increases unsaturated fatty 
acid oxidation.  A, H9C2 cardiomyocytes were transfected (efficiency ~ 50%) with the 
indicated plasmids and incubated with 
14
C oleate.  Accumulation of acid soluble 
14
CO2 
over time was used to monitor rates of fat oxidation and quantified by scintillation 
counting.  Oleate metabolism was significantly increased only when both mUCP3 and 
mDCI were co-expressed.  B, In contrast to unsaturated fatty acid oxidation, the UCP3 – 
DCI complex does not increase oxidation of the saturated FA palmitate.  H9C2 
cardiomyocytes were transfected (efficiency ~ 50%) with the indicated plasmids and 
incubated with 
14
C palmitate.  Accumulation of acid soluble 
14
CO2 over time was used to 
monitor rates of fat oxidation and quantified by scintillation counting.  Palmitate 
metabolism was unchanged with single transfection or when both mUCP3 and mDCI 
were co-expressed when compared to vector controls.    Statistical evaluation was 
performed using the student‟s t-test with significance set a priori at p<0.05.  Data 
represent averages with error bars representing standard error of the mean (SEM) from at 
least 3 independent experiments.   









Figure 4.18 The DxxK Motif In UCP3 and DCI is Necessary For Binding.  A, 
Sequence alignment reveals a homologous Asp X X Lys (DxxK) putative binding motif in 
the 2
nd
 matrix loop of mUCP3 and at amino acids 305-308 of mDCI.  B, The DIIK motif 
in DCI confers binding to UCP3.  HeLa cells were transfected with the indicated 
plasmids (below panels), immunoprecipitated with anti-myc or the negative control 
IgG2A, followed by anti-V5 immunoblotting.  As shown, only full length mDCI-myc 
bound full length mUCP3 (lane 2).  UCP3-V5 was not bound by IgG2A (lane 1), or by the 
mDCI∆DIIK-myc mutant (lane 4).  As shown in Fig. 3, mDCI-myc failed to bind 









Figure 4.19 DCI – UCP3 binding is required for augmentation of oleate 
oxidation.  H9C2 cardiomyocytes were transfected with the indicated plasmids and 
incubated with 
14
C oleate.  The augmentation of fatty acid oxidation seen with wild-type 
mUCP3 and mDCI overexpression was blocked by expression of either the mDCI∆DIIK-
myc mutant or the UCP3∆HD4A-V5 in combination with the wild type complex 
counterpart.  Moreover, co-expression of mDCI∆DIIK-myc and UCP3∆HD4A-V5 
significantly decreased oleate oxidation compared to baseline vector only controls.  
Statistical evaluation was performed using the student‟s t-test with significance set a 
priori at p<0.05.  Data represent averages with error bars representing standard error of 






Experiments in cells, mitochondria, reconstituted liposomes, and planar lipid bilayers 
have demonstrated the requirement of FA for activation of UCPs (Jezek 1999; Skulachev 
1999; Hagen and Lowell 2000; Zackova, Skobisova et al. 2003).  However, little is 
known about the mechanisms by which fatty acids regulate UCP function.  The bulk of 
literature indicates that UCP3 may function to coordinate the mitochondrial disposal 
(metabolism and transport) of fatty acids as a means of defending skeletal muscle from 
lipid and oxidant toxicity during conditions of increased fat oxidation (e.g. fasting, 
exercise, high fat diet)(Dulloo, Samec et al. 2001; Schrauwen, Hesselink et al. 2002; 
Schrauwen and Hesselink 2004; Brand and Esteves 2005).  Indeed, UCP3 activation 
increases thermogenic fat oxidation and protects against obesity-induced insulin 
resistance and diabetes in mice (Choi, Fillmore et al. 2007).  Saturated fatty acids (e.g. 
palmitate) are the prime culprits of metabolic suppression and inflammation induced by 
lipid overload (Weigert, Brodbeck et al. 2004).  In contrast, recent work shows that both 
unsaturated fatty acids (e.g. oleate) and UCP3 increase lipid oxidation and protect from 
saturated fat-induced mitochondrial dysfunction and insulin resistance (Coll, Eyre et al. 
2008; Gao, Griffiths et al. 2009).  Coincidentally, unsaturated fatty acids (e.g. 
arachidonate, linoleate) are strong inducers of UCP-mediated proton leak in vitro 
(Zackova, Skobisova et al. 2003).  We found that oleate sharply increases UCP3-
dependent respiration in primary myotubes (Figure 4.13 B).   
     Interestingly, oleate and structurally-related “healthy” fatty acids require double bond 





Figure 4.20 Proposed model of UCP3-DCI complex function.  Unsaturated fatty 
acids, including arachidonate, oleate, and the essential FAs linolenate and linoleate, 
undergo hydrocarbon chain shortening by beta oxidation until the process is stalled by 
double bonds encountered at odd numbered carbon positions.  Two pathways restore the 
beta oxidation of these metabolites.  The „isomerase-dependent‟ pathway does not utilize 
DCI.  The „DCI-dependent‟ pathway will produce FA species with double bonds in the 3 
and 5 positions.  DCI is the only enzyme identified that can metabolize these 3,5 dienoyl-
CoA intermediates.  Thus, without DCI, these intermediates would accumulate and 
sequester matrix CoA stores, leading to global inhibition of beta oxidation. UCP3, in 
addition to its protonophoric action, shares with DCI the proposed function of disposing 
of (through transport albeit) unmetabolizeable fatty acids.  Thus, we propose a model 
where the UCP3:DCI complex functions as a fatty acid oxidation / proton transporting 
hub that matches unsaturated fatty acid metabolism with substrate and CoA availability 







 dienoyl-CoA  isomerase (DCI) is required for a percentage of 
metabolites produced by FAs with similar double bond configurations as oleate(Shoukry 
and Schulz 1998; Liang, Zhu et al. 1999).  The ubiquitous tissue expression of DCI 
combined with its conservation through evolution in yeast, plant, and mammals suggest 
the importance of its function.  We have shown, as in previous reports, that DCI contains 
a mitochondrial and peroxisomal targeting sequence (Filppula, Yagi et al. 1998; Zhang, 
Liang et al. 2001).  The atypical presence of two targeting signals suggests DCI responds 
to nutrient sensing or selective shuttling to a certain subcellular compartment 
(mitochondria versus peroxisomes) as has been shown for other proteins (Elgersma, van 
Roermund et al. 1995; Lee, Lee et al. 2006).   
     We discovered that UCP3 interacts directly, at endogenous levels, and in an oleate-
regulated manner with DCI (Figures 4.10, 4.14).  Moreover, we also found that 
DCI:UCP3 synergized to increase oleic acid metabolism in myotubes (Figure 4.13 B).  
Finally, we observed that oleate treatment of primary myotubes increased the binding of 
UCP3:DCI in vivo, oleate-increased UCP3-dependent thermogenesis in wild type but not 
UCP3-null myotubes, (Figure 4.14) and C14 radiolabelled oleate metabolism was 
synergistically increased by the coexpressed wild type DCI and UCP3 compared to single 
DCI or UCP3 transfected myotubes (Figure 4.17 A).  
     Immunoprecipitation experiments with UCP3 mutants lacking amino acids 134-146, 
the first third of the central matrix loop, show strongly decreased DCI binding (Figures 
4.11, 4.12).  This same region contains an ASP Val Val Lys (DVVK) motif postulated by 
Jezek‟s group to be involved in fatty acid regulation of UCPs (Jezek and Urbankova 
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2000).  Interestingly, a similar DIIK motif lies next to the active site pocket of DCI 
(Modis, Filppula et al. 1998) and thus may represent a common fatty acid interaction 
domain.   
     Combined, these results support our overall hypothesis that UCP3 mediates 
unsaturated FA-induced thermogenic lipid disposal.  These findings are consistent with 
previous theories by Harper (Himms-Hagen and Harper 2001; Seifert, Bezaire et al. 
2008) which propose UCP3 functions to maintain Coenzyme A availability, but not as an 
integral part of FAO.  As represented in the proposed model (Figure 4.20), enoyl-CoA‟s 
produced from unsaturated FAs with double bonds in odd positions enter the beta 
oxidation system.  Metabolites produced by enoyl-CoA isomerase (ECI) will shuttle FAs 
towards the „reductase pathway‟.  Without the presence of DCI these metabolites would 
be allowed to accumulate, depleting CoA stores, and subsequently inhibiting beta 
oxidation.  The UCP3:DCI complex serves to synergistically metabolize fatty acids 
through isomerazation of double-bonds and uncoupling. 
     Although previous knockout studies in yeast have shown little phenotype in the 
absence of DCI (Gurvitz, Mursula et al. 1999), other studies in C. Elegans have shown 
the robust and physiologically relevant consequence of FA accumulation (Van Gilst, 
Hadjivassiliou et al. 2005).  Future directions for this research include the development of 
a DCI knockout mouse, which may have substantial morbidity depending on the 
percentage and type of fatty acids in the diet.  In addition, determination of DCI: UCP3 
complex activity and function from healthy and insulin-resistant diabetic skeletal muscle 
samples will be important.  We predict that UCP3 and DCI interact in a nutrient-
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dependent manner regulated by a consensus DxxK amino acid motif and when bound 
coordinately activate uncoupling and disposal of fatty acids, and protect from saturated 




Chapter 5 – Concluding remarks and future directions 
 Since its discovery in 1997, no consensus has been reached by the scientific 
community on its physiologic or biochemical functions of Uncoupling Protein 3 (UCP3).  
Thus, this work sought to address gaps in the knowledge surrounding UCP3 function 
through the study of its anatomical location of action and protein-protein binding 
partners.   Although initially thought to play a role in cold-induced adaptive 
thermogenesis similar to UCP1, that theory was later disproven by the observation that 
UCP3 knockout animals respond normally to cold exposure (Vidal-Puig, Grujic et al. 
2000).  It is widely held that UCP1 is the only uncoupling protein able to mount an 
inducible thermogenic response in animals (Nedergaard, Matthias et al. 1999).  Previous 
studies with MDMA (Mills, Banks et al. 2003) and our studies with methamphetamine, 
lipopolysaccharide showing that thermogenic responses to these agents are 80-100% 
attenuated in UCP3 knockout animals challenge this long held view.  Our observation 
that skeletal muscle UCP3 can mediate a significant, non-shivering inducible 
thermogenic response therefore represents a significant paradigm shift.   
UCP3 protein expression has been convincingly demonstrated in only three 
tissues – heart, brown fat, and skeletal muscle (Vidal-Puig, Solanes et al. 1997).  Among 
these tissues, UCP3-dependent mitochondrial uncoupling has only been observed in 
skeletal muscle, the most highly metabolic organ in humans – representing 40% of 
human body mass and 30% of overall oxygen consumption.  UCP3 in rodent brown 
adipose tissue is thought not to mediate significant thermogenesis; this is evident in large 
part because BAT (via UCP1) in UCP3 knockout animals generates heat and maintains 
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normal body temperature when animals are exposed to cold (Liebig, von Praun et al. 
2004). A large misconception in the clinical and scientific literature concerning the 
mechanisms by which muscle generates heat is that it mainly involves some combination 
of shivering (muscle work / contraction), the sarcoplasmic Ca
++
-ATPase ryanodine 
receptor, or other calcium handling mechanisms (McCoy, Renfrew et al. 1994).  
Shivering, which requires calcium for contraction, indeed is an early component of the 
thermogenic adaptation to cold and infection, and contraction or any manner of 
significant muscle work is thermogenic.  However, shivering is not only metabolically 
demanding to the organism, but may also compromise oxygenation and is therefore 
disabling.  Following cold exposure and infection, shivering apparently “kick starts” 
thermogenesis, but it soon wanes as non-shivering thermogenic responses take over.  In 
response to feeding and activation of the SNS, shivering is not reported to play any role 
in the thermogenic response.   
With regard to the ryanodine receptor, certain mutations in this protein in humans 
and pigs give rise to malignant hyperthermia, a rare pharmacogenetic disorder that 
expresses when patients are administered triggering agents such as volatile anesthetics.  
Dantrolene specifically binds and inhibits the ryanodine receptor, and is a very effective, 
life-saving treatment for malignant hyperthermia (Blank and Boggs 1993).  However, 
despite its use in the clinic (because of the assumption that hyperthermia in people is 
generally ryanodine-dependent), no evidence establishes that dantrolene effectively 
lowers body temperature in response to any other hyperthermia or fever-inducing 
condition, including MDMA hyperthermia, septic fever, neuroleptic malignant syndrome, 
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thyrotoxicosis, etc.  Likewise, it has been shown that dantrolene has no effect on 
MDMA-induced heat production in rats, indicating that the ryanodine receptor is not 
involved in the MDMA response (Rusyniak, Banks et al. 2004).  Previously published 
studies show that ATP levels rapidly decline in skeletal muscle in vivo after MDMA 
administration, a hallmark of strong mitochondrial uncoupling (Rusyniak, Tandy et al. 
2005).  Since UCP3 mediates 80% of the thermogenic response to MDMA, all other 
potential mediators (UCP1, ryanodine receptor, etc.) play a relatively minor role (≤20% 
of the response).   UCP3 in skeletal muscle may be a relevant mediator of human 
inducible thermogenesis.   
In most, if not all cases, thermogenic responses to physiologic stimuli (e.g. cold, 
feeding, infection,) and pathologic stimuli (thyrotoxicosis, amphetamine hyperthermia, 
pheochromocytoma) are integrated centrally in the hypothalamus and lead to the 
activation of the SNS and NE release into the bloodstream.  NE primarily binds to β3-
adrenoreceptors in endothelial, adipose, and skeletal muscle tissues.  Upon activation B3-
ARs mediate the activation of lipases in target tissues leading to the systemic conversion 
of triglycerides (TGs) to free fatty acids (FFAs) and the accumulation of FA in the 
bloodstream, adipose, and muscle tissues.  FAs in the bloodstream are taken up into 
thermogenic, metabolically active tissue such as brown fat and skeletal muscle to be used 
as fuel for work, or heat production.  In cells, isolated mitochondria, and recombinant 
purified liposomal systems, FAs have been well established to be required for the 
activation of uncoupling proteins.  Multiple fatty acid species and other lipid messengers 
bind and activate UCP-dependent proton leak across mitochondrial or liposomal 
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membranes (Matthias, Ohlson et al. 2000; Zackova, Skobisova et al. 2003).  The highest 
affinity FA ligands for UCP1 and UCP3 include the long chain fatty acids oleic, 
palmitoleic, and lauric acids, and bind to each UCP with a similar affinity (Zackova, 
Skobisova et al. 2003).  In addition, FA added to cultured primary brown adipocytes also 
directly activate UCP1 thermogenesis (Matthias, Ohlson et al. 2000).  Thus, the 
activation of uncoupling proteins by fatty acids is likely intimately tied to their function. 
The biochemical function of UCP3 has long been the source of speculation by 
many laboratories.  It has been proposed to decrease reactive oxygen species (ROS), 
prevent insulin resistance, combat obesity, prevent lipotoxicity, and increase metabolism 
of fatty acids.  In attempting to analyze UCP3 function by looking for protein bindings 
partners, we discovered a novel interaction with the fatty acid oxidation enzyme DCI.  
The complex formed by UCP3 and DCI is the first mitochondrial UCP3 protein 
interaction reported.  In addition to its novelty, this complex also has functional 
consequences by increasing fatty acid oxidation and preventing accumulation of toxic 
lipid metabolites.  The study presented herein provides supporting evidence for the 
inducible, thermogenic capacity of skeletal muscle UCP3.  Likewise, through the 
discovery of protein binding partners, the role of UCP3 in preventing mitochondrial 
lipotoxicity is more clear.  Collectively, the findings presented in this work will 
contribute to the understanding of thermogenic proton leak and energy wasting in 
humans.   
In humans, the direct mechanisms that mediate thermogenesis in response to 
stimulation of the SNS have not been identified, and therefore no treatments exist for 
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most types of hyperthermic illness.  Identification of thermogenic mediators is required 
for the development of anti-hyperthermic agents.  On the other hand, safe stimulation of 
thermogenesis is a promising approach for the development of more effective anti-
obesity therapies.  This promising strategy also requires the identification of thermogenic 
mediators so that heat production can be more accurately titrated than is possible with 
current (and dangerous) thermogenic treatments (e.g. systemic stimulants, ephedra).  We 
have identified a novel, UCP3-mediated thermogenic pathway that can be stimulated by a 
variety of inducing agent, in different animal species and mouse strains.  These studies 
will offer new insights into thermoregulation in general.  And are expected to illuminate 
molecular mechanisms by which uncoupling proteins may regulate proton leak and fatty 
acid metabolism that have remained largely unknown since UCP1 was first discovered 
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